[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 288
1. Sakakura C, Hasegawa K, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Yazumi S, Yamagishi H, Okanoue T, Chiba T, Hagiwara A: Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res; 2005 Sep 15;11(18):6479-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
  • PURPOSE: Our previous results suggested that a lack of RUNX3 function contributed to human gastric carcinogenesis, but the role of RUNX3 in progression and metastasis remains unclear.
  • We examined RUNX3 expression in clinical samples of peritoneal metastases in gastric cancers.
  • Changes in metastatic potential were assessed in animal experiments using stable RUNX3 transfectants of gastric cancer cells.
  • EXPERIMENTAL DESIGN AND RESULTS: Significant down-regulation of RUNX3 through methylation on the promoter region was observed in primary tumors (75%) as well as in all clinical peritoneal metastases of gastric cancers (100%) compared with normal gastric mucosa.
  • Interestingly, it strongly inhibited peritoneal metastases of gastric cancers in animal model (P < 0.01).
  • Microarray analysis identified approximately 28 candidate genes under the possible downstream control of RUNX3, some of these genes were considered to be possibly involved in peritoneal metastases, which were related to signal transduction (vav3, TOLL-like receptor, MAPKK, MET, S1 00A1 1, and cathepsin E), apoptosis (caspase 9), immune responses (CD55 and TLR1O), and cell adhesion (sialyltransferase 1 and galectin 4).
  • CONCLUSION: These results indicate that silencing of RUNX3 affects expression of important genes involved in aspects of metastasis including cell adhesion, proliferation, apoptosis, and promoting the peritoneal metastasis of gastric cancer.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Silencing / physiology. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology. Transcription Factors / genetics
  • [MeSH-minor] Animals. Apoptosis / drug effects. Base Sequence. Blotting, Northern. Cell Line, Tumor. Cell Proliferation / drug effects. Core Binding Factor Alpha 3 Subunit. DNA Methylation. Down-Regulation / genetics. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Mice. Mice, Nude. Molecular Sequence Data. Neoplasm Transplantation. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Homology, Nucleic Acid. Transfection. Transforming Growth Factor beta / pharmacology. Transforming Growth Factor beta1. Transplantation, Heterologous. Up-Regulation / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166423.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Runx3 protein, human; 0 / Runx3 protein, mouse; 0 / TGFB1 protein, human; 0 / Tgfb1 protein, mouse; 0 / Transcription Factors; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


2. Abbas SM, Merrie AE: Resection of peritoneal metastases causing malignant small bowel obstruction. World J Surg Oncol; 2007;5:122
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of peritoneal metastases causing malignant small bowel obstruction.
  • BACKGROUND: Resection of peritoneal metastases has been shown to improve survival in patients with abdominal metastatic disease from abdominal or extra abdominal malignancy.
  • This study evaluates the benefit of peritoneal metastatic resection in patients with malignant small bowel obstruction and a past history of treated cancer.
  • PATIENTS AND METHODS: Patients undergoing laparotomy for resection of peritoneal metastases from recurrence of previous cancer between 1992-2003 were reviewed retrospectively.
  • Data were collected about type of primary cancer, interval to recurrence, extent of the disease and completeness of resection, morbidity and mortality and long-term survival.
  • RESULTS: Between 1992 and 2003 there were 79 patients (median age 62, range 19-91) who had laparotomy for small bowel obstruction due to recurrent cancer.
  • The primary cancer was colorectal (31), gynaecologic cancer (19), melanoma (16) and others (13).
  • Median survival was 5 months; patients with history of colorectal cancer had better survival than other cancer (median survival 7 months vs. 4 months; p = 0.02).
  • CONCLUSION: Laparotomy for small bowel obstruction is a worthwhile option for patients with malignant small bowel obstruction.
  • [MeSH-major] Intestinal Obstruction / surgery. Intestine, Small. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Surg. 2000 Oct;43(5):353-8 [11045093.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):862-9 [11313174.001]
  • [Cites] Ann Surg Oncol. 2001 Sep;8(8):632-7 [11569777.001]
  • [Cites] AJR Am J Roentgenol. 2002 Feb;178(2):283-90 [11804881.001]
  • [Cites] Nucl Med Commun. 2002 Oct;23(10):975-82 [12352596.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):519-28 [13678719.001]
  • [Cites] Invest Radiol. 2004 Jan;39(1):8-12 [14701983.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1420-9 [15007086.001]
  • [Cites] Br J Surg. 1984 Dec;71(12):933-5 [6208964.001]
  • [Cites] J Surg Oncol. 1990 Apr;43(4):209-13 [1691417.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):367-71 [2022140.001]
  • [Cites] Am J Surg. 1991 Dec;162(6):624-8 [1727026.001]
  • [Cites] Arch Surg. 1995 Aug;130(8):832-6; discussion 836-7 [7632142.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):336-44 [10379853.001]
  • (PMID = 17958911.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2206041
  •  go-up   go-down


3. Mahteme H, Sundin A, Larsson B, Khamis H, Arow K, Graf W: 5-FU uptake in peritoneal metastases after pretreatment with radioimmunotherapy or vasoconstriction: an autoradiographic study in the rat. Anticancer Res; 2005 Mar-Apr;25(2A):917-22
Hazardous Substances Data Bank. NORBORMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-FU uptake in peritoneal metastases after pretreatment with radioimmunotherapy or vasoconstriction: an autoradiographic study in the rat.
  • This study was conducted to test if tumour drug uptake could be increased in experimental colorectal cancer peritoneal metastases, by using pretreatment with peritoneal vasoconstriction or radioimmunotherapy.
  • A total of 29 nude rats with peritoneal metastases were injected intraperitoneally (i.p.) with 14C-labelled 5-FU.
  • Peritoneal tumours in group II were of smaller size (median area 308 pixels) than in group I (619 pixels), in group III (901 pixels), in group IV (769 pixels) and in group V (808 pixels).
  • These results demonstrate that 5-FU uptake in experimental peritoneal metastases is increased when the peritoneal absorption of the drug is blocked using pretreatment with a vasoconstrictive agent.
  • This principle may also be relevant when treating patients with colorectal cancer peritoneal metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antimetabolites, Antineoplastic / pharmacokinetics. Fluorouracil / pharmacokinetics. Immunotoxins / pharmacology. Norbornanes / pharmacology. Peritoneal Cavity / blood supply. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868928.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antimetabolites, Antineoplastic; 0 / Carbon Radioisotopes; 0 / Carcinoembryonic Antigen; 0 / Immunotoxins; 0 / Iodine Radioisotopes; 0 / Norbornanes; K4085589CZ / norbormide; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Tischoff I, Tannapfel A: [Pathologic and anatomic evidence of peritoneal metastases]. Chirurg; 2007 Dec;78(12):1085-6, 1088-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic and anatomic evidence of peritoneal metastases].
  • Peritoneal metastases are secondary tumours of the peritoneum and the most common tumours at this location.
  • Ovarian carcinoma, colorectal cancer, and gastric cancer are the most frequent ones that show peritoneal involvement, along with carcinomas of the pancreas, gallbladder, uterus, and lung.
  • Primary tumours originating in the peritoneum such as malignant peritoneal mesothelioma, primary peritoneal carcinoma, and benign peritoneal tumours along with inflammatory and reactive lesions must be differentiated from peritoneal metastases.
  • Especially in cancer of unknown primary tumour, the discrimination between primary peritoneal tumours and peritoneal metastases is difficult and often requires immunohistochemical identification.
  • [MeSH-major] Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritonitis / pathology. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030433.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Kim SR, Ikawa H, Ando K, Mita K, Fuki S, Imoto S, Shimizu K, Kanbara Y, Sugimoto K, Fujii M, Kudo M, Matsuoka T, Hayashi Y: Small hepatocellular carcinoma presenting with massive metastasis in the peritoneum, mimicking sarcomatous tumor. Hepatol Res; 2007 Oct;37(10):885-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small hepatocellular carcinoma presenting with massive metastasis in the peritoneum, mimicking sarcomatous tumor.
  • The case of a 51-year-old man with hepatitis C virus (HCV)-related hepatocellular carcinoma metastasizing to the peritoneal cavity and mimicking a sarcomatous tumor is presented.
  • A 12 x 12 cm mass, disclosed by computed tomography (CT), in the peritoneal cavity was predominantly isodense to muscle but had hypodense areas that suggested necrosis.
  • Further studies may provide insights into the metastatic modes of HCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17573942.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Lum DJ, King AR: Peritoneal metastases from an atypical fibroxanthoma. Am J Surg Pathol; 2006 Aug;30(8):1041-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal metastases from an atypical fibroxanthoma.
  • Atypical fibroxanthoma (AFX) is a mesenchymal neoplasm usually occurring in sun-exposed skin of elderly patients.
  • The majority have an excellent prognosis, as recurrences are uncommon and metastases are rare.
  • We present a case of an 81-year-old man who developed widespread peritoneal metastases from an AFX on his scalp, which was completely excised 3 years earlier.
  • Histology of the scalp lesion showed a markedly pleomorphic neoplasm characteristic of AFX.
  • Features associated with increased risk of metastasis, namely lymphovascular space invasion, deep invasion, and substantial necrosis, were not present.
  • Histologically, the peritoneal tumor was virtually identical to the original scalp lesion and had an identical immunohistochemical profile.
  • Electron microscopy of the peritoneal tumor revealed pleomorphic undifferentiated cells with abundant lipid vacuoles.
  • This is the first reported case of AFX with peritoneal metastases.
  • Although AFXs generally have an excellent outcome, pathologists must remain cognizant of the small but real potential for metastasis and this needs to be conveyed in all reports.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Histiocytoma, Malignant Fibrous / secondary. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861978.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Lee YT, Ng EK, Hung LC, Chung SC, Ching JY, Chan WY, Chu WC, Sung JJ: Accuracy of endoscopic ultrasonography in diagnosing ascites and predicting peritoneal metastases in gastric cancer patients. Gut; 2005 Nov;54(11):1541-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoscopic ultrasonography in diagnosing ascites and predicting peritoneal metastases in gastric cancer patients.
  • BACKGROUND: Preoperative diagnosis of peritoneal metastases (PM) is difficult in patients with gastric cancer (GC).
  • The diagnosis of PM was confirmed by histopathology or peritoneal fluid cytology.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / ultrasonography. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascites / ultrasonography. Endosonography. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1999;29(2):111-5 [10030734.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):520-4 [10027323.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2509-12 [10484016.001]
  • [Cites] Am J Surg. 1999 Sep;178(3):256-62 [10527450.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):342-7 [10433041.001]
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):336-9 [11522974.001]
  • [Cites] J Clin Gastroenterol. 2002 Oct;35(4):321-7 [12352295.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1407-12 [12960184.001]
  • [Cites] Gastrointest Endosc. 2004 Apr;59(4):471-4 [15044880.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1521-5 [15083179.001]
  • [Cites] Ann R Coll Surg Engl. 1974 May;54(5):219-28 [4275295.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1984;25(5):375-8 [6391091.001]
  • [Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]
  • [Cites] Br J Surg. 1989 Oct;76(10):1036-9 [2532050.001]
  • [Cites] Gut. 1991 May;32(5):479-82 [2040468.001]
  • [Cites] Gut. 1993 May;34(5):604-10 [8504959.001]
  • [Cites] Gastrointest Endosc. 1994 Jul-Aug;40(4):442-6 [7926534.001]
  • [Cites] J Trauma. 1995 Aug;39(2):375-80 [7674411.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1995 Jul;5(3):549-57 [7582581.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):872-5 [9149204.001]
  • [Cites] Surg Laparosc Endosc. 1998 Apr;8(2):132-5 [9566568.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):27-32 [9915239.001]
  • [CommentIn] Gut. 2006 Oct;55(10):1524; author reply 1524 [16966710.001]
  • (PMID = 15955787.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774738
  •  go-up   go-down


8. Benedict SP, Ahuja M, Mammen KJ: Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature. Indian J Urol; 2010 Apr;26(2):287-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature.
  • Peritoneal carcinomatosis is rare in prostate cancer especially in the absence of skeletal or other visceral metastases.
  • We report a case of hormone refractory adenocarcinoma prostate presenting with only peritoneal metastases and massive malignant ascites.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877611.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2938557
  • [Keywords] NOTNLM ; Metastasis / peritoneum / prostate cancer
  •  go-up   go-down


9. Untereiner V, Piot O, Diebold MD, Bouché O, Scaglia E, Manfait M: Optical diagnosis of peritoneal metastases by infrared microscopic imaging. Anal Bioanal Chem; 2009 Mar;393(6-7):1619-27
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical diagnosis of peritoneal metastases by infrared microscopic imaging.
  • Fourier transform infrared (FTIR) spectroscopy is nowadays widely accepted as a technique with high potential for diagnosis of cancerous tissues.
  • This study presents an example of the investigation of peritoneal metastases by FTIR microimaging.
  • Peritoneal malignancies are generally secondary localizations of primary visceral cancers such as ovarian, stomach or colon cancers.
  • By analysing simultaneously both formalin-fixed paraffin-embedded and frozen specimens, we examined malignant and non-malignant (i.e. fibrotic and cicatricial) peritoneal lesions.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Peritoneal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Multivariate Analysis. Paraffin Embedding. Sensitivity and Specificity. Spectroscopy, Fourier Transform Infrared / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19219424.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Nered SN, Klimenkov AA: [Surgery for gastric carcinoma in patients with high risk of peritoneal metastases]. Vopr Onkol; 2005;51(1):75-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery for gastric carcinoma in patients with high risk of peritoneal metastases].
  • Survival in 242 cases of lymph dissection (D2) and 319 patients with (D1) operated on for gastric cancer was compared.
  • D2 lymph dissection was not followed by higher survival rates in dealing with such gastric malignancies involving high risk of peritoneal metastases as signet ring cell, undifferentiated cell, diffuse-infiltrative, Borrmann type IV gastric cancer and complete involvement of the stomach.
  • When D2 lymphoadenectomy was carried out for gastric adenocarcinoma, generally known to be rarely accompanied by peritoneal metastases, the end results were much better, even in cases of serosal invasion.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures / adverse effects. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909812.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


11. Arnold D, Lordick F: [Systemic treatment of peritoneal metastases]. Chirurg; 2007 Dec;78(12):1117-22
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic treatment of peritoneal metastases].
  • Peritoneal metastases are common in metastatic disease of many tumour types and thus are determinant for prognosis and development of tumour-related symptoms that jeopardise quality of life.
  • Systemic chemotherapy has proven efficacious in improving both prognosis and quality of life in numerous tumour types and should therefore be considered as part of the treatment strategy--although there is no large body of data from predefined cohorts with"only peritoneal" manifestation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Camptothecin / toxicity. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Combined Modality Therapy. Fluorouracil / administration & dosage. Fluorouracil / toxicity. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / toxicity. Neoplasm Staging. Prognosis. Quality of Life

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18004522.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB: Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg; 2005 Mar;200(3):371-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer.
  • BACKGROUND: Identification of extracellular matrix proteins (ECM) associated with tumor cell metastasis may generate targets for future therapy against pancreatic cancer metastases.
  • We hypothesized that comparison of ECM-associated gene expression in primary and metastatic pancreatic tumors would identify ECM proteins associated with pancreatic metastasis.
  • STUDY DESIGN: A clinically relevant model of pancreatic cancer was used to generate RNA from primary and metastatic tumors; it was evaluated by microarray analysis with subsequent cluster analysis.
  • RESULTS: Peritoneal metastases at sites distant from the primary tumor were present in all animals bearing orthotopic tumors.
  • High-density microarray comparison of gene expression in metastases versus primary pancreatic tumors identified a greater than twofold increase in the expression of Cyr61, a secreted matricellular protein that binds to integrins.
  • Reverse transcription polymerase chain reaction confirmed the microarray results, and immunohistochemistry analysis demonstrated increased Cyr61 protein and persistent alpha(v)beta(3) expression in peritioneal metastases.
  • Additionally, immunohistochemistry demonstrated increased collocalization of Cyr61 and alpha(v) in metastases relative to primary tumor.
  • CONCLUSIONS: The ECM protein Cyr61 shows increased expression in metastatic lesions in a clinically relevant model of pancreatic adenocarcinoma.
  • Protein analysis confirms the microarray results and collocalization of Cyr61, and alpha(v) suggests that interaction between Cyr61 and alpha(v)beta(3) promotes formation of peritoneal metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic / genetics. Immediate-Early Proteins / genetics. Intercellular Signaling Peptides and Proteins / genetics. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Animals. Antibodies, Neoplasm / immunology. Cluster Analysis. Cysteine-Rich Protein 61. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Neoplasm Transplantation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737847.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / CYR61 protein, human; 0 / Cyr61 protein, mouse; 0 / Cysteine-Rich Protein 61; 0 / Extracellular Matrix Proteins; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


13. Voermans RP, Sheppard B, van Berge Henegouwen MI, Fockens P, Faigel DO: Comparison of Transgastric NOTES and laparoscopic peritoneoscopy for detection of peritoneal metastases. Ann Surg; 2009 Aug;250(2):255-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Transgastric NOTES and laparoscopic peritoneoscopy for detection of peritoneal metastases.
  • OBJECTIVE: To create a model of peritoneal metastases for development of TGP and to employ this model to compare TGP to LAP.
  • METHODS: Small beads were stapled in porcine peritoneal cavities to simulate metastases.
  • RESULTS: Locations of beads included: abdominal peritoneum (14 beads), diaphragm (11), surface of liver and hepatoduodenal ligament (32), and miscellaneous sites (7).
  • TGP was superior for detecting beads on the abdominal and diaphragmatic peritoneum than for the liver, namely TGP-s: 23/25 (92%) versus 12/32 (38%) (P < 0.001); TGP-t: 25/25 (100%) versus 11/32 (34%) (P < 0.001).
  • CONCLUSION: In this first prospective, blinded, comparative trial TGP was inferior to LAP for the detection of simulated metastases.
  • [MeSH-major] Laparoscopy / methods. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Animals. Disease Models, Animal. Female. Gastrostomy. Observer Variation. Omentum. Peritoneal Cavity. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2010 Jun;251(6):1193-4; author reply 1194-5 [20485117.001]
  • (PMID = 19638914.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Atassi Z, Varga D, Plotzki K, Kurzeder C, Kreienberg R: Peritoneal metastases in breast cancer patients: Differences in survival depending on histological subtype. J Clin Oncol; 2009 May 20;27(15_suppl):e12024

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal metastases in breast cancer patients: Differences in survival depending on histological subtype.
  • : e12024 Background: Distant spread from breast cancer is commonly found in bones, lungs, liver, and central nervous system.
  • Metastatic involvement of peritoneum and retroperitoneum is unusual and unexpected.
  • The aim of the study was to perform a comprehensive analysis of breast cancer patients with peritoneal metastases and to compare survivals depending on biological subtypes.
  • METHODS: 44 breast cancer pts with peritoneal metastases were detected out of a database of 2,500 breast cancer patients treated in one institution between 1995 and 2005.
  • Clinical characteristics such as estrogen receptor and progesterone receptor as well as survivals were analized based on breast cancer subtypes.
  • Median survival calculated from peritoneal metastases in histologic subgroups was as follows: Median progression free survival was 36.5 months for ductal invasive carcinoma, and 23.5 months for lobular invasive breast cancer.
  • Median overall survival was 46 (Std 38.5) months for ductal invasive breast cancer and 32 (Std 54.5) months for lobular invasive breast cancer.
  • CONCLUSIONS: Patients with peritoneal metastases are a heterogenous group with a different outcome.
  • The histologic subtype seems to be an important predictive factor as lobular invasive breast cancer is associated with worsened progression free an overall survival rates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964300.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Tuthill MH, Pell R, Giuliani R, Adrian L, Lewis JS, Leonard R, Coombes C, Stebbing J: Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):e12023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis.
  • : e12023 Background: We are observing increasing numbers of patients with advanced breast cancer and peritoneal metastases.
  • METHODS: The electronic imaging database at Charing Cross Hospital was searched for the terms 'breast,' 'cancer or tumor,' 'peritoneal,' and 'ascites' from 2000-2008.
  • Those with confirmed peritoneal disease from breast cancer, as described on ultrasound or staging CT reports with a clinico-pathologic confirmed diagnosis, were included in the study.
  • A subsequent total of 44 individuals (2.7% of the metastatic cohort) were included in this study, as having breast cancer with peritoneal secondaries.
  • While the median survival from the diagnosis of metastatic breast cancer measured 20.5 months (range 0.1 -125 months), the median survival of patients with peritoneal disease was 1.56 months (range 0.2 - 27 months).
  • CONCLUSIONS: Our data shows that the median survival of patients with peritoneal breast cancer metastasis is surprisingly poor, with only a minority surviving more than six months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964303.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Espino-Strebel E, Luna JT: Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer.
  • : e16524 Background: Poor prognostic factors dictating the need for extended surgical staging among endometrial cancer patients can be accurately determined only after laparotomy.
  • This prospective study was conducted to determine the correlation between preoperative serum CA125 and surgicopathologic prognostic factors in endometrial cancer.
  • METHODS: Endometrial cancer patients diagnosed from October 2006 to July 2008 who were eligible for primary surgical treatment were included.
  • All patients underwent laparotomy, peritoneal fluid cytology, extrafascial/radical hysterectomy, bilateral salpingooophorectomy, bilateral pelvic lymph node dissection, and para-aortic lymph node sampling.
  • Specimens were examined for tumor differentiation, lymphovascular space invasion, depth of myometrial invasion, cervical, adnexal, and vaginal involvement, pelvic and para-aortic lymph node metastases, and peritoneal fluid cytology.
  • Preoperative serum CA125 was significantly correlated with deep myometrial invasion (p = 0.02), adnexal metastasis (p = 0.01), pelvic (p < 0.01), and para-aortic node involvement (p<0.01).
  • CONCLUSIONS: Preoperative serum CA125 has a significant correlation with deep myometrial invasion, adnexal metastasis, pelvic and para-aortic lymph node involvement, and extrauterine disease at a cutoff value of 55U/mL.
  • It is recommended that serum CA125 determination be part of the preoperative work-up of endometrial cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960797.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Nakai Y, Isayama H, Sasaki T, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M: The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study. J Clin Oncol; 2009 May 20;27(15_suppl):e15648

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study.
  • : e15648 Background: S-1 was reported to be active against gemcitabine (Gem)-refractory pancreatic cancer (PaC) in Japan and was introduced in February 2005 in our institution.
  • The introduction rates of second-line chemotherapy and the causes of introduction failure were assessed.
  • There were no differences in baseline characteristics at PD for Gem between PreS-1 and PostS-1 Groups, except for metastasis to peritoneum more prevalent in PreS-1 Group (44.7% in PreS-1 Group and 23.0% in PostS-1 Group, p=0.023).
  • The introduction rate of second-line chemotherapy increased from 12.8% in PreS-1 Group to 45.9% in PostS-1 Group.
  • Second-line chemotherapy was administered in 34 pts, 29 by S-1, 4 by 5-FU-based chemoradiation, and 1 by 5-FU.
  • The causes of introduction failure of second line chemotherapy were poor PS in 64.9%, patients' refusal in 16.2%, infection in 2.7%, adverse effects of Gem in 1.4% and jaundice in 1.4%.
  • RR, PFS, and OS for second-line S-1 were 17.2%, 2.5 Mo, and 7.8 Mo, respectively.
  • The Cox hazard model revealed PreS-1 Group (HR2.42, p=0.001) in addition to male gender (HR1.83, p=0.019), poor PS (HR3.52, p<0.001), liver metastasis (HR2.36, p=0.037), elevated LDH (per 100U/L increase) (HR 1.30, p=0.046), elevated CRP (HR 1.14, p=0.023) at PD for Gem as poor prognostic factors of RS for Gem-refractory PaC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962734.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • Three patients with pT3 had recurrence of pleural dissemination (n=1), lymph node metastases (n=1), or pulmonary metastases and peritoneal dissemination (n=1).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fujiwara S, Hasuike Y, Fukuchi N, Hayashi N, Kida H, Tsujie M, Yoshida T, Ebisui C, Sakita I, Fujimoto T: [Efficacy of the combination therapy in early stage of recurrent cholangio celluler carcinoma (CCC)]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1849-51
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of cholangio celluler carcinoma (CCC) with a good quality of life, in spite of the recurrence of peritoneum and portal hepatic lymph nodes (PHLN), due to the combination therapy that consisted of hepatic arterial infusion, systemic chemotherapy, radiation therapy and an insertion of a metallic stent into the bile duct.
  • Ten months later, metastases to peritoneum and portal hepatic lymph nodes were found, so the resection of the peritoneum was performed, and cells in ascites were defined to be positive with cytology.
  • After 2 years from the first operation, the size of portal hepatic lymph nodes had grown and both the billilbin and tumor marker levels had increased, so we started systemic chemotherapy, radiation therapy and insertion of a metallic stent into the bile duct.
  • The tumor marker level decreased in a short time.
  • [MeSH-minor] Combined Modality Therapy. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / prevention & control. Peritoneum / surgery. Quality Control. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315960.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Kornovski Ia, Genev P: [Surgical treatment of fallopian tube carcinoma with metastases in the pelvic peritoneum, cervix uteri (septum rectovaginale), and the colon transversum]. Akush Ginekol (Sofiia); 2007;46(8):27-31
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of fallopian tube carcinoma with metastases in the pelvic peritoneum, cervix uteri (septum rectovaginale), and the colon transversum].
  • This article presents a 66-year-old woman with carcinoma of the left uterine tube, metastases in the peritoneum, colon transversum, pelvic lymph nodes, omentum and septum rectovaginale.
  • The surgical treatment and the histopathological findings have been reported, as well as a brief review of the literature in terms of forms, diagnosis, clinical signs and prognosis of the carcinoma of the uterine tube.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18642553.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


21. Bertolotto M, Quaia E, Zappetti R, Cester G, Turoldo A: Differential diagnosis between splenic nodules and peritoneal metastases with contrast-enhanced ultrasound based on signal-intensity characteristics during the late phase. Radiol Med; 2009 Feb;114(1):42-51
Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis between splenic nodules and peritoneal metastases with contrast-enhanced ultrasound based on signal-intensity characteristics during the late phase.
  • PURPOSE: This study was done to assess the enhancement characteristics of splenic implants and to evaluate whether contrast-enhanced ultrasound (CEUS) after SonoVue injection allows the differential diagnosis with peritoneal metastases.
  • MATERIAL AND METHODS: Thirteen consecutive patients with splenosis and 13 consecutive patients with peritoneal metastases were investigated with CEUS after injection of 2.4 ml of SonoVue.
  • Average signal intensity was evaluated by measuring the average grey level in a region of interest encompassing the entire nodule.
  • Metastases presented with variable enhancement and progressive washout.
  • Starting from 90 s after injection, there was no overlapping between enhancement of splenic grafts and peritoneal metastases, and only splenic grafts showed a percent of enhancement higher than 60% of the maximum enhancement.
  • CONCLUSIONS: CEUS after SonoVue injection may be considered a valuable alternative to scintigraphy for characterising peritoneal splenic grafts without radiation.
  • [MeSH-major] Peritoneal Neoplasms / ultrasonography. Spleen / ultrasonography. Splenosis / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Observer Variation. Phospholipids / administration & dosage. Retrospective Studies. Software. Splenectomy. Statistics, Nonparametric. Sulfur Hexafluoride / administration & dosage. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956146.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


22. Bruin SC, Verwaal VJ, Vincent A, van't Veer LJ, van Velthuysen ML: A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin. Ann Surg Oncol; 2010 Sep;17(9):2330-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin.
  • OBJECTIVE: To predict clinical outcome by classification of peritoneal metastases (PM) of colorectal or appendiceal origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / pathology. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232161.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Koppe MJ, Oyen WJ, Bleichrodt RP, Verhofstad AA, Goldenberg DM, Boerman OC: Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother Radiopharm; 2006 Oct;21(5):506-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
  • The aim of the present studies was to investigate whether the efficacy of radioimmunotherapy (RIT) using the (131)I-labeled anti-CEA monoclonal antibody (MAb) MN-14 could be enhanced by coadministration of gemcitabine in nude mice with small (1-3 mm) peritoneal metastases of colonic origin.
  • Gemcitabine monotherapy at 0.11 mg or 0.33 mg/mouse/administration every 3rd day (total, 4 administrations) resulted in a median survival of 52 and 57 days, respectively (p = 0.0003, compared to controls).
  • RIT alone resulted in a median survival of 66 days (p < 0.0001, compared to controls).
  • The combination of RIT and gemcitabine coadministration resulted in a median survival of 73 and 94 days, respectively (p = 0.12, for trend).
  • In the second therapy study, median survival of the control mice was 48 days, which was similar to the median survival of the mice treated with daily administrations of gemcitabine monotherapy at 0.022 mg/mouse/administration on 5 consecutive days (49 days; p = 0.17).
  • RIT alone resulted in a significantly improved median survival of 66 days (p= = 0.0010, compared to controls).
  • Combination therapy using RIT and gemcitabine resulted in a median survival of 64 days, which did not differ significantly from the survival of the mice treated with RIT alone (p = 0.43).
  • CONCLUSIONS: At the dose regimens employed, gemcitabine did not enhance the efficacy of RIT of experimental small-volume peritoneal carcinomatosis of colonic origin.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Deoxycytidine / analogs & derivatives. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy. Radioimmunotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105422.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


24. Mabille M, Vanel D, Albiter M, Le Cesne A, Bonvalot S, Le Péchoux C, Terrier P, Shapeero LG, Dromain C: Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!). Eur J Radiol; 2009 Feb;69(2):204-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).
  • MATERIALS AND METHODS: This prospective CT study evaluated 107 consecutive patients with advanced metastatic GIST treated with Imatinib.
  • RESULTS: Seventy patients had total or partial cystic-like transformation of hepatic and/or peritoneal metastases.
  • Forty-six patients developed metastases, 17 patients showed increasing parietal thickness and 29 patients with peripheral enhancing nodules.
  • CONCLUSION: The development of peripheral thickening or enhancing nodules within cystic-like metastatic lesions, even without any change in size, represented progressive GIST under Imatinib, growing in a short time and should alert the clinician for the possible need for a change in therapy.
  • [MeSH-major] Gastrointestinal Stromal Tumors. Liver Neoplasms. Peritoneal Neoplasms. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046841.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


25. Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, Allameh AA: High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr Purif; 2005 Nov;44(1):32-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The high binding activity to MUC1 antigen purified from ascitic fluid (of patients with small-cell lung aggressive carcinoma and metastasis to peritoneum) and the very close similarity of these molecules to human VHs illustrated the potential application of these novel products as an immunodiagnostic and immunotherapeutic reagent.
  • [MeSH-minor] Animals. Camels / immunology. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / immunology. Carcinoma, Small Cell / secondary. Humans. Immunologic Tests / methods. Mice. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / secondary. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Recombinant Proteins / isolation & purification

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922625.001).
  • [ISSN] 1046-5928
  • [Journal-full-title] Protein expression and purification
  • [ISO-abbreviation] Protein Expr. Purif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Variable Region; 0 / Mucin-1; 0 / Recombinant Proteins
  •  go-up   go-down


26. Vanel D, Albiter M, Shapeero L, Le Cesne A, Bonvalot S, Le Pechoux C, Terrier P, Petrow P, Caillet H, Dromain C: Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol; 2005 Apr;54(1):118-23
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.
  • PURPOSE: To prospectively analyze the evolution of hepatic and peritoneal unresectable metastases from gastrointestinal stromal tumors (GIST) under imatinib mesylate, a new targeted treatment, which induces changes in lesion structure.
  • MATERIALS AND METHODS: 54 patients with metastases from GIST underwent an abdominal and pelvic computed tomography examination without and with contrast enhancement, before and during treatment with imatinib mesylate.
  • RESULTS: 27 patients presented with both hepatic and peritoneal metastases, 14 had only peritoneal and 13, only hepatic disease.
  • On baseline imaging, all metastases were hypodense heterogeneous lesions with progressive, concentric enhancement.
  • After treatment (mean duration of follow-up: 23 months) metastases decreased in size number and enhancement in 35/54 patients, remained stable in 2 patients and increased in 14 patients.
  • In 13/39 patients with hepatic metastases a cyst-like appearance was noted.
  • Reactivation after a partial response appeared first as a focal, peripheral, solid nodule in the wall of a cystic lesion, or an increase in lesion density, before size regrew.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / radiography. Peritoneal Neoplasms / secondary. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797301.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Contrast Media; 0 / Piperazines; 0 / Pyrimidines; 4419T9MX03 / Iohexol; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


27. Ina K, Furuta R, Kataoka T, Nishio T, Nagao S, Kayukawa S, Masaki A, Ando T, Goto H: [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):979-81
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
  • Two unresectable advanced gastric cancer cases with peritoneal metastases were successfully treated by the combination therapy of S-1 and paclitaxel.
  • Case 1: 65-year-old male (performance status: PS 3) with type 1 gastric cancer with malignant ascites.
  • Case 2: 66-year-old male (PS3) with peritoneal metastases whose primary gastric lesion was surgically resected.
  • Combination therapy of S-1 and paclitaxel can be highly recommended for patients with inoperable gastric cancer with poor PS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542719.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


28. Yoshida K, Yamaguchi S, Kawaguchi A: [A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection]. Gan To Kagaku Ryoho; 2007 Apr;34(4):601-4
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection].
  • The patient was a 50-year-old male with advanced gastric cancer.
  • Laparoscopy showed peritoneal metastases.
  • Laparoscopy showed no peritoneal metastasis, and thus a total gastrectomy with splenectomy and D 2 lymph node dissection was performed.
  • The pathological diagnosis was sig, LM, type 4, pT 3 (SE), sci, INFgamma, ly 0, v 0, pN 0, pPM (-), pDM (-), and the antitumor efficacy of this therapy was Grade 0 histologically.
  • Combined chemotherapy of biweekly paclitaxel and TS-1 was thought to be an effective neoadjuvant chemotherapy for advanced gastric cancer in this case.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431348.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


29. Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol; 2010 Jan;17(1):89-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
  • BACKGROUND: The present study investigated the clinical significance of S100 calcium binding protein A4 in the development, progression, and metastasis of gastric cancer.
  • METHODS: Tumor tissue, adjacent normal tissue, and lymph node and peritoneal metastases were obtained from patients with gastric cancer, and their gene expression profiles were analyzed by Affymetrix GeneChip HG-U133A2.0 array.
  • The expression of S100A4 was detected by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) in gastric tumor tissue and lymph node and peritoneum metastasis.
  • Immunohistochemistry was employed to analyze S100A4 expression in 436 clinicopathologically characterized gastric cancer cases and in corresponding distant metastases from 61 patients.
  • The expression of S100A4 in lymph node and peritoneal metastases was significantly higher than that in gastric tumor tissue.
  • The expression of S100A4 messenger RNA (mRNA) or protein differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph node and peritoneal metastases.
  • Further multivariate analysis suggested that depth of invasion, lymph node and distant metastases, tumor-node-metastasis (TNM) stage, and upregulation of S100A4 were independent prognostic indicators for the disease.
  • Expression of S100A4 in gastric cancer is associated significantly with lymph node and distant metastases, and poor prognosis.
  • S100A4 may be a useful marker to predict development, progression, and metastasis of gastric cancer.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Gastrectomy. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820999.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


30. Sato A, Nakamachi M: [Gastric cancer]. Gan To Kagaku Ryoho; 2009 Feb;36(2):176-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric cancer].
  • The prognostic significance of histologic type is unclear in patients with gastric cancer.
  • The differentiated type is related to metastasis in the liver and the undifferentiated type to the peritoneum metastasis.
  • CPT-11 and CPT-11+ CDDP combined therapy, which is the second-line therapy, can be expected to be effective in a gastric cancer patient with target lesion like liver metastasis.
  • With paclitaxel and docetaxel, the second-line therapy, the effect is expected in a gastric cancer patient without a target lesion like peritoneal metastasis.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Akiyoshi T, Oya M, Fujimoto Y, Kuroyanagi H, Ueno M, Yamaguchi T, Takahashi S, Hatake K, Katori M, Yamamoto N, Muto T: Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case. Surg Today; 2010 Mar;40(3):272-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case.
  • A 70-year-old woman with a pelvic tumor had undergone exploratory laparoscopy at another institution, which revealed many peritoneal nodules.
  • Immunohistochemical staining of a biopsy specimen of the peritoneal nodules was positive for KIT.
  • Laparotomy revealed complete regression of the peritoneal lesions.
  • We report this case to show that there is the possibility of curative salvage surgery after long-term imatinib treatment in some patients with peritoneal metastases of a GIST.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Gastrointestinal Stromal Tumors / surgery. Ileal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180084.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


32. Kim JC, Hong HK, Lee KH, Ka IH, Roh SA, Koo KH, Kim HC, Oh ST, Oh SJ, Kim JS, Park KC: Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab')2. J Cancer Res Clin Oncol; 2005 Aug;131(8):495-503
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental radioimmunoguided surgery for peritoneal metastases of gastric cancer using anticarcinoembryonic antigen-specific T84.66 F(ab')2.
  • PURPOSE: In gastric cancer, peritoneal dissemination is the most frequent cause of the noncurative resection and recurrence after curative resection.
  • We therefore evaluated the feasibility of radioimmunoguided surgery (RIGS) in the treatment of peritoneal metastases of gastric cancer and the use of anti-CEA-specific T84.66 F(ab')2 as an efficient immune agent.
  • METHODS: Two human gastric cancer cell lines, MKN45 and RF48, were intraperitoneally xenografted into nude mice, which were later injected with 125I-labeled T84.66 F(ab')2.
  • Peritoneal tumors were localized by RIGS 5 days after antibody injection.
  • RESULTS: We observed 37 peritoneal metastases: 8 invisible (long diameter, <1 mm), 6 small (1- < 5 mm), and 23 large (> or =5 mm) tumors.
  • The accuracy, sensitivity and specificity of RIGS in detecting peritoneal metastasis were 82% (69/84), 76% (28/37), and 87% (41/47), respectively.
  • Mean scores of CEA immunostaining and silver grains in tumors were significantly higher than those in the nontumor-bearing peritoneum (P < 0.001).
  • CONCLUSIONS: 125I-labeled T84.66 F(ab')2 efficiently targeted peritoneally disseminated gastric cancer cells, suggesting that RIGS using this immune agent may accurately detect occult peritoneal metastases in patients with gastric cancer.
  • [MeSH-major] Carcinoembryonic Antigen / immunology. Peritoneal Neoplasms / radionuclide imaging. Peritoneal Neoplasms / surgery. Radioimmunodetection / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887029.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Carcinoembryonic Antigen; 0 / Immunoglobulin Fragments; 0 / Iodine Radioisotopes
  •  go-up   go-down


33. Kitazume Y, Satoh S, Taura S, Kimula Y: Diffusion-weighted magnetic resonance imaging detection of renal cancer presenting with diffuse peritoneal metastases in a patient with hemodialysis-associated acquired cystic disease of the kidney. J Magn Reson Imaging; 2009 Apr;29(4):953-6
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging detection of renal cancer presenting with diffuse peritoneal metastases in a patient with hemodialysis-associated acquired cystic disease of the kidney.
  • It was difficult to detect renal cancer, which was revealed as a primary site of peritoneal metastases by autopsy, with conventional cross-sectional imaging, such as enhanced computed tomography and T2, T1, and dynamic gadolinium-enhanced T1-weighted magnetic resonance imaging, because multiple renal cysts caused marked distortion of the renal parenchyma and the cancer had necrosis.
  • We demonstrated the usefulness of diffusion-weighted imaging with a high b-factor to detect renal cancer presenting with peritoneal metastasis in a patient with ACDK.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Kidney Diseases, Cystic / etiology. Kidney Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Renal Dialysis / adverse effects


34. Bai FH, Wang J, Zhao PT, Cao SS, Lei T, Li Y, Wu KC, Fan DM: [Preliminary screening and identification of a peptide that binds specifically to gastric cancers cells with high metastasis to peritoneum]. Zhonghua Yi Xue Za Zhi; 2006 Mar 14;86(10):659-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preliminary screening and identification of a peptide that binds specifically to gastric cancers cells with high metastasis to peritoneum].
  • OBJECTIVE: To screen and identify peptides that binds specifically to gastric cancers cells with high metastasis to peritoneum so as to find appropriate vectors for targeting therapy for cancer.
  • METHODS: Human gastric cancer cells of the line GC9811 and those with high metastasis to peritoneum of the line GC9811-P were co-incubated with the 12-mer bacteriophage random peptide library.
  • Forty-eight hours later the mice were killed and the peritoneum and tumor masses in different organs were collected and under fluorescence microscopy.
  • The peritoneal tumor tissues caused by the GC9811-P cells of the mice showed strong fluorescence and those caused by GC9811 cells only showed very weak fluorescence.
  • CONCLUSION: The sequence SMSIASPYIALE that specifically binds to human gastric cancer cells with high metastasis has been screened that has the potential to be used as a marker and targeting vector in diagnosis and treatment of gastric cancer.
  • [MeSH-major] Peptide Library. Peptides / metabolism. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Flow Cytometry. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Microscopy, Fluorescence. Neoplasm Transplantation. Neoplasms, Experimental / metabolism. Protein Binding

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681920.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  •  go-up   go-down


35. Ando M, Nagahama T, Fukuda A, Ami K, Kurokawa T, Hataji K, Ganno H, Kawasaki N, Arai K, Okada Y, Tei S: [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2288-90
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly colon cancer patient with hepatic, lunge and peritoneal metastases was treated by hepatic arterial infusion and systemic chemotherapy-a case report].
  • A-75 year-old man, diagnosed as ascending colon cancer with large bowel obstruction, multiple hepatic, lunge metastases and peritoneal dissemination, was treated with neoadjuvant chemotherapy (FOLFOX4: 2 courses) and subsequent ileocecal resection.
  • [MeSH-minor] Aged. Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage

  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224550.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol; IFL protocol
  •  go-up   go-down


36. Ogawa M, Kosaka N, Choyke PL, Kobayashi H: H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol; 2009 Jul 17;4(7):535-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo molecular imaging with target-specific activatable "smart" probes, which yield fluorescence only at the intended target, enables sensitive and specific cancer detection.
  • To demonstrate the fluorescence activation effect during in vivo fluorescence endoscopic molecular imaging, a highly quenched probe, avidin-TAMRA, or a minimally quenched probe, avidin-Alexa488, was administered into mice with ovarian metastases to the peritoneum.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2006 Oct;12(10):1213-9 [17013385.001]
  • [Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72 [15601762.001]
  • [Cites] J Chem Inf Comput Sci. 1987 Feb;27(1):21-35 [3558506.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3271-5 [15132531.001]
  • [Cites] J Am Chem Soc. 2002 Jan 16;124(2):196-204 [11782171.001]
  • [Cites] Science. 2001 May 18;292(5520):1385-8 [11359013.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2791-9 [17363601.001]
  • [Cites] J Am Chem Soc. 2007 Apr 4;129(13):3918-29 [17352471.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6335-43 [17975145.001]
  • [Cites] Anal Sci. 2008 Jan;24(1):51-3 [18187849.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Bioconjug Chem. 2008 Aug;19(8):1735-42 [18610943.001]
  • [Cites] Nat Med. 2009 Jan;15(1):104-9 [19029979.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):232-9 [19139133.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1268-72 [19176373.001]
  • [Cites] Mol Pharm. 2009 Mar-Apr;6(2):386-95 [19718793.001]
  • [Cites] Anal Biochem. 1999 Dec 1;276(1):27-35 [10585741.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • (PMID = 19480464.001).
  • [ISSN] 1554-8937
  • [Journal-full-title] ACS chemical biology
  • [ISO-abbreviation] ACS Chem. Biol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Receptors, Cell Surface; 0 / Rhodamines; 0 / galactose receptor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS122733; NLM/ PMC2743556
  •  go-up   go-down


37. Bai F, Liang J, Wang J, Shi Y, Zhang K, Liang S, Hong L, Zhai H, Lu Y, Han Y, Yin F, Wu K, Fan D: Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer. J Mol Med (Berl); 2007 Feb;85(2):169-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.
  • Peritoneal dissemination in gastric cancer is the most frequent cause of the noncurative resection and recurrence after curative resection.
  • We, therefore, evaluated the feasibility of a peptide, which was obtained by screening a random phage display library, in the treatment of peritoneal metastases of gastric cancer.
  • In this study, a novel cell line, GC9811-P, with a high potential peritoneal metastasis of gastric cancer derived from its parental cell line, GC9811, was established.
  • The isolated phage-displaying peptide, SMSIASPYIALE (named peptide PIII), was obtained after four rounds of selection, showing a tendency to preferentially bind to GC9811-P cells compared with a panel of other gastric cancer cell lines, and preferentially accumulate in peritoneal metastasis tumor tissue in comparison with control organs, peritoneum, liver, pancreas, spleen, lung, and kidney.
  • Furthermore, a highly reproducible animal experimental model of gastric cancer with peritoneal dissemination was established in nude mice by injecting a suspension of the cell line into the gastric wall of nude mice.
  • Animals intraperitoneally treated with peptide PIII in this model or another animal model of gastric cancer with peritoneal dissemination established using MKN45 cells showed suppressed tumor metastasis to peritoneum and significantly prolonged survival.
  • In conclusion, the selected peptide PIII was a biologically active peptide and could effectively inhibit peritoneal dissemination of gastric cancer.
  • [MeSH-major] Neoplasm Metastasis / drug therapy. Peptides / therapeutic use. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Mice. Mice, Nude. Neoplasm Invasiveness / prevention & control. Neoplasm Transplantation. Peptide Library. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043801.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  •  go-up   go-down


38. Zhang KD, Guo XN, Yang L, Zhang DT, Bai FH, Jiang HP, Zhai HH, Nie YZ, Wu KC, Fan DM: [Screening and identification of phage-displayed polypeptides specifically binding to human gastric cancer with high metastatic potential to peritoneum]. Zhonghua Zhong Liu Za Zhi; 2005 Jul;27(7):397-400
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening and identification of phage-displayed polypeptides specifically binding to human gastric cancer with high metastatic potential to peritoneum].
  • OBJECTIVE: By means of phage-display technique, to screen polypeptides that specifically bind to human gastric cancer with high metastatic potential to peritoneum.
  • METHODS: Two human gastric cancer cell lines were used: GC9811-P with high metastatic potential to peritoneum and its wild type parental GC9811, to carry out subtractive screening with a phage display-12 peptide library.
  • When injected into the peritoneal cavity of nude mice, 6 of the 40 clones did not bind to mouse peritoneum as examined by immunohistochemical staining.
  • CONCLUSION: Two peptides have been obtained that specifically bind to a gastric cancer cell variant GC9811-P, which easily disseminates to the peritoneum.
  • Whether or not they could block GC9811-P metastasis to peritoneum in vivo remains to be determined.
  • [MeSH-major] Peptide Library. Peptides / metabolism. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16188121.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Peptide Library; 0 / Peptides
  •  go-up   go-down


39. Snyder MJ, Bentley R, Robboy SJ: Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis. Int J Gynecol Pathol; 2006 Apr;25(2):155-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transtubal spread of serous adenocarcinoma of the endometrium: an underrecognized mechanism of metastasis.
  • However, uterine serous carcinomas (USCs) metastasize frequently to peritoneal surfaces even when only minimally invasive.
  • Primary peritoneal cases and cases with significant ovarian involvement were excluded.
  • Fifty-four of 87 (62%) had extrauterine spread at hysterectomy, most commonly to peritoneal surfaces and sometimes to the pelvic lymph nodes.
  • Eleven of these 54 (20%) patients with metastases lacked both myometrial and LV invasion, and the metastases involved the peritoneal surface more often than the lymph nodes (p<0.001).
  • Another 13 cases also had clusters of tumor within the fallopian tube lumen, and all 16 cases had peritoneal spread (p<0.001).
  • Retrograde transtubal implantation as well LV invasion are two important mechanisms by which USC spreads; all cases with tumor clusters in the fallopian tube lumen had peritoneal spread.
  • This explains the phenomenon whereby patients with serous carcinomas confined to the endometrium and lacking LV invasion have widespread metastases to the peritoneum.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Adenocarcinoma, Scirrhous / secondary. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Neoplasm Metastasis
  • [MeSH-minor] Fallopian Tubes / pathology. Female. Humans. Hysterectomy. Neoplasm Invasiveness. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633065.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Seshimo A, Mitsuhashi M, Aratake K, Ogawa S, Itabashi M, Shirotani N, Kameoka S: [Prediction and treatment of peritoneal dissemination in gastric cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1393-7
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prediction and treatment of peritoneal dissemination in gastric cancer].
  • In advanced gastric cancer, the frequency of relapses such as metastasis to the peritoneum is high.
  • Moreover, 13 cases of P 0 were also positive.
  • These drugs were effective even in carcinoma of the peritoneum, and an improvement in the prognosis can be expected.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Floxuridine / administration & dosage. Humans. Ileus / etiology. Ileus / surgery. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritoneal Cavity / cytology. Peritoneal Lavage. Predictive Value of Tests. Prognosis. Pyridines / administration & dosage. Survival Rate. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


41. Longacre TA, Oliva E, Soslow RA, Association of Directors of Anatomic and Surgical Pathology: Recommendations for the reporting of fallopian tube neoplasms. Hum Pathol; 2007 Aug;38(8):1160-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By convention, epithelial tumors that involve the ovary or peritoneal surfaces are considered to have arisen either in the ovary or endometrium or, in absence of significant ovarian or endometrial involvement, in the peritoneum, irrespective of whether or not the fallopian tube mucosa is also involved.
  • An alternative hypothesis for the origin of ovarian and peritoneal carcinoma has even been proposed, based on the concept of transport and implantation of malignant cells from the tube to the ovary and peritoneum.
  • Malignancies in the fallopian tube can therefore be classified as (1) arising primarily in the fallopian tube, either from preexisting endometriosis (or more rarely, a mature teratoma) or directly from tubal mucosa with metastasis to adjacent tissues;.
  • (2) arising in the ovary, endometrium, or peritoneum with metastasis to the tubal serosa or mucosa; or (3) arising primarily in the fallopian tube as well as in the ovary, endometrium, or peritoneum (simultaneous primary tumors).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Apr;40(4):603-4 [19289185.001]
  • (PMID = 17270244.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M, Orlando C: The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis; 2009;26(3):261-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CXCR4/CXCL12 axis in endometrial cancer.
  • Chemokines and their receptors seem to act as important regulators of the metastatic cascade.
  • CXCL12 and its receptor CXCR4 were shown to be involved in human cancer progression.
  • There is increasing evidences suggesting that the expression of CXCR4 in human cancers is correlated with poor patient prognosis and that CXCR4 neutralization can prevent metastases in vivo.
  • Here we tested the role of the CXCR4/CXCL12 axis in a neoplasia with a reduced risk of metastatic progression, such as human endometrial cancer.
  • The expression of CXCR4 was predominant in endometrial cancer (P = 0.035) whereas CXCL12 was overexpressed in normal mucosae (P = 0.002).
  • CXCR4 expression (P = 0.035), but not CXCL12, was significantly related to cancer differentiation.
  • Endometrial cancer cells (HEC1A) were able to generate diffuse metastases in peritoneum, lung and liver of CD-1 nude mice, but the simultaneous treatment with a neutralizing anti-CXCR4 monoclonal antibody dramatically reduced the number and the size of metastases in the animals.
  • In conclusion, our data seem to indicate that the CXCR4-CXCL12 axis can play a role in the progression of endometrial carcinoma and that specific therapies with antagonists of chemokines receptors could be of help in the treatment of metastatic patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Animals. Antibodies, Monoclonal / pharmacology. Cell Line, Tumor. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19199057.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR; 0 / Receptors, CXCR4
  •  go-up   go-down


43. Nakajima TE, Yanagihara K, Takigahira M, Yasunaga M, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Mihara K, Ochiya T, Matsumura Y: Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res; 2008 Nov 15;68(22):9318-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
  • Moreover, we have reported the strong antitumor activity of NK012 (i.e., SN-38-releasing polymeric micelles) against human cancer xenografts compared with CPT-11.
  • Here, we investigated the advantages of NK012 over CPT-11 treatment in mouse models of gastric cancer with peritoneal dissemination.
  • NK012 or CPT-11 was i.v. administered thrice every 4 days at their respective maximum tolerable doses (NK012, 30 mg/kg/day; CPT-11, 67 mg/kg/day) to mice receiving orthotopic transplants of gastric cancer cell lines (44As3Luc and 58As1mLuc) transfected with the luciferase gene (n = 5).
  • SN-38 concentration in gastric tumors and peritoneal nodules was examined by high-performance liquid chromatography (HPLC) 1, 24, and 72 hours after each drug injection.
  • High concentrations of SN-38 released from NK012 were detected in gastric tumors and peritoneal nodules up to 72 hours by HPLC.
  • NK012 also showed antitumor activity against peritoneal nodules.
  • Thus, NK012 showing enhanced distribution with prolonged SN-38 release may be ideal for cancer treatment because the antitumor activity of SN-38 is time dependent.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010905.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Micelles; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. D'Annibale M, Esposito A, Boschetto A, Marandino F, Lonardo MT, Vennarecci G: Solitary peritoneal metastases from ductal breast cancer. Chir Ital; 2007 Mar-Apr;59(2):191-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary peritoneal metastases from ductal breast cancer.
  • The principal sites of metastases are the regional lymph nodes, liver, lung and bone; unusual sites of metastases are very rare.
  • After 4 years, the presence of a pelvic mass in the absence of local, distant or lymph node recurrence was found.
  • The pathological and immunohistochemical examination revealed a metastatic carcinoma compatible with a mammalian origin.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500175.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


45. Till H, Bergmann F, Metzger R, Haeberle B, von Schweinitz D, Prosst R: Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats. J Pediatr Surg; 2006 Aug;41(8):1357-60
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic fluorescence diagnosis of peritoneal metastases from human hepatoblastoma in nude rats.
  • AIM: Fluorescence diagnosis is gaining clinical importance for the detection of malignancies in various medical disciplines.
  • The technique relies on the specific metabolic capacity of a lesion to produce a fluorescent compound.
  • METHODS: Human HB (3 x 10(6)) cells were laparoscopically injected (4 mm scope, 18-G needle) underneath the peritoneum of 7 nude rats (mean weight, 198 g).
  • Photosensitization was induced by peritoneal lavage with aminolevulinic acid (3%).
  • After 3 hours, the animals were investigated with white light laparoscopy (WL) and laparoscopic fluorescence diagnosis (LFD), applying the Storz PDD system.
  • CONCLUSION: Human HB can be detected with LFD in a rat model.
  • This finding opens a wide spectrum of experimental and clinical investigations to evaluate the impact of fluorescence diagnosis for pediatric oncology.
  • [MeSH-major] Fluorescence. Hepatoblastoma / diagnosis. Laparoscopy. Liver Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aminolevulinic Acid / metabolism. Animals. Cell Line, Tumor. Disease Models, Animal. Fluorescent Dyes / metabolism. Humans. Neoplasm Transplantation. Rats

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863837.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


46. Li SD, Howell SB: CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm; 2010 Feb 1;7(1):280-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
  • Intraperitoneal (ip) chemotherapy increases the survival of optimally debulked patients with ovarian cancer due to direct access of the drug to tumor nodules growing on the peritoneal surface.
  • To further improve efficacy, we sought to develop a cisplatin-loaded microparticle that would target to CD44 on cancer cells when injected ip.
  • Clearance of Hyplat from the mouse peritoneum was reduced by 7-fold and tumor uptake was increased by 2- to 3-fold in CD44-positive but not CD44-negative tumor models compared to that attained with free cisplatin.
  • Hyplat was more effective than cisplatin at slowing the growth of intraperitoneally inoculated A2780 ovarian cancer cells and improving survival thus demonstrating the potential of Hyplat to enhance the efficacy of ip chemotherapy.
  • [MeSH-major] Antigens, CD44 / metabolism. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994852.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents; 0 / CD44 protein, human; 9004-61-9 / Hyaluronic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


47. Yokosuka K, Ishii R, Suzuki Y, Hirano K, Ishii N, Sekihara Y, Hamazaki S, Nishimura H: Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report. Neurol Med Chir (Tokyo); 2007 Jun;47(6):273-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastasis of high grade glioma without simultaneous central nervous system recurrence: case report.
  • A 21-year-old man presented with extraneural metastases to the peritoneum, pleura, bone marrow, lymph nodes, and other organs from a pulvinar high grade glioma.
  • Two and a half years after the last surgery, extraneural metastasis to the peritoneal cavity was discovered.
  • He died 13 months after the occurrence of extraneural metastases and 10 years after the initial diagnosis.
  • Autopsy revealed tumor masses in the peritoneum, pleura, bone marrow, lymph nodes, and other organs, but no recurrent tumor of the primary lesion or metastases to other areas in the central nervous system.
  • Systemic metastases from primary intracranial tumors are rare, but are likely to become more frequent as the prognosis of patients with brain tumors improves and the duration of survival lengthens.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / pathology. Glioma / secondary. Neoplasm Metastasis / physiopathology. Peritoneal Neoplasms / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Central Nervous System / pathology. Drug Therapy. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Pulvinar / pathology. Pulvinar / physiopathology. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587781.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Okamoto T, Tsuburaya A, Kameda Y, Yoshikawa T, Cho H, Tsuchida K, Hasegawa S, Noguchi Y: Prognostic value of extracapsular invasion and fibrotic focus in single lymph node metastasis of gastric cancer. Gastric Cancer; 2008;11(3):160-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of extracapsular invasion and fibrotic focus in single lymph node metastasis of gastric cancer.
  • BACKGROUND: Histological findings of metastatic lymph nodes are important prognosticators in patients with gastric cancer.
  • The aim of this study was to clarify the clinical significance of various pathological characteristics of the early phase of lymph node metastasis in patients with gastric cancer, by selecting patients with tumors that had single lymph node metastases, no serosal invasion, and no metastases to the peritoneum, liver, or distant organs.
  • These patients were subdivided according to the following histological characteristics of the one metastatic lymph node: size of the metastasis (i.e., amount of tumor cells [AT]), proliferating pattern (PP), intranodal location (IL), and the presence or absence of extracapsular invasion (ECI) and/or fibrotic focus (FF).
  • ECI and FF were observed significantly more frequently in pT2 than in pT1 cancer.
  • CONCLUSION: These results strongly suggested that the presence of ECI or FF could affect the survival of patients with gastric cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Fibrosis / pathology. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825310.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Longmire MR, Ogawa M, Hama Y, Kosaka N, Regino CA, Choyke PL, Kobayashi H: Determination of optimal rhodamine fluorophore for in vivo optical imaging. Bioconjug Chem; 2008 Aug;19(8):1735-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Optical imaging has the potential to improve the efficacy of surgical and endoscopic approaches to cancer treatment; however, the optimal type of fluorescent probe has not yet been established.
  • In the present study, we conjugated 4 common rhodamine-core based fluorescent dyes to a clinically feasible and quickly internalizing D-galactose receptor targeting reagent, galactosamine serum albumin (GmSA), and conducted a series of in vitro and in vivo experiments using a metastatic ovarian cancer mouse model to determine if differences in optical imaging properties exist among rhodamine fluorophores and if so, which rhodamine core possesses optimal characteristics for in vivo imaging applications.
  • Herein, we demonstrate that the rhodamine-fluorophore, TAMRA, is the most robust of the 4 common rhodamine fluorophores for in vivo optical imaging of ovarian cancer metastases to the peritoneum.
  • [MeSH-minor] Animals. Cattle. Cell Line, Tumor. Feasibility Studies. Female. Flow Cytometry. Fluorescence. Galactosamine / metabolism. Galactose / metabolism. Humans. Hydrogen-Ion Concentration. Intracellular Space / metabolism. Mice. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Protein Denaturation. Serum Albumin / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2007 Nov;98(11):1727-33 [17784874.001]
  • [Cites] Trends Biotechnol. 2008 Jan;26(1):1-4 [18037177.001]
  • [Cites] Curr Opin Chem Biol. 2003 Oct;7(5):626-34 [14580568.001]
  • [Cites] Oncology. 1990;47(2):177-84 [2314830.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):2042-7 [9158003.001]
  • [Cites] J Am Chem Soc. 2005 Apr 6;127(13):4888-94 [15796553.001]
  • [Cites] Invest Radiol. 2005 Jun;40(6):321-7 [15905717.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14404-9 [16183744.001]
  • [Cites] Mol Imaging. 2006 Jul;5(3):188-97 [16954034.001]
  • [Cites] Bioconjug Chem. 2006 Nov-Dec;17(6):1426-31 [17105220.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3809-17 [17440095.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6335-43 [17975145.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051501 [17994865.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):195-208 [12541130.001]
  • (PMID = 18610943.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010657-03; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Rhodamines; 0 / Serum Albumin; 7535-00-4 / Galactosamine; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ NIHMS122719; NLM/ PMC2756081
  •  go-up   go-down


50. Voermans RP, Faigel DO, van Berge Henegouwen MI, Sheppard B, Fockens P: Comparison of transcolonic NOTES and laparoscopic peritoneoscopy for the detection of peritoneal metastases. Endoscopy; 2010 Nov;42(11):904-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of transcolonic NOTES and laparoscopic peritoneoscopy for the detection of peritoneal metastases.
  • METHODS: Small beads were stapled into porcine peritoneal cavities to simulate metastases.
  • RESULTS: Locations of beads included abdominal peritoneum (6 beads), diaphragm (8), liver (18), and miscellaneous sites (1).
  • The majority of missed beads were located at the inferior liver surface: TCP-s detected 8/15 (53%) and TCP-t 5/15 (33%) of these simulated metastases.
  • [MeSH-major] Laparoscopy / methods. Natural Orifice Endoscopic Surgery / methods. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 21072705.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Kato Y, Yashiro M, Noda S, Tendo M, Kashiwagi S, Doi Y, Nishii T, Matsuoka J, Fuyuhiro Y, Shinto O, Sawada T, Ohira M, Hirakawa K: Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer; 2010 Mar 2;102(5):898-907
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma.
  • Tumour hypoxia reported to be associated with more aggressive tumour phenotypes such as high metastatic ability and resistance to various anti-cancer therapies which may lead to a poorer prognosis.
  • METHODS: We established a scirrhous gastric carcinoma cell line (OCUM-12) from ascites associated with scirrhous gastric carcinoma, and a hypoxia-resistant cancer cell line (OCUM-12/Hypo) was cloned from OCUM-12 cells by continuous exposure to 1% oxygen.
  • RESULTS: Histologic findings from orthotopic tumours derived from parent OCUM-12 cells and daughter OCUM-12/Hypo cells revealed poorly differentiated adenocarcinoma with extensive fibrosis that resembled human scirrhous gastric cancer.
  • The OCUM-12/Hypo orthotopic models developed multiple metastases to the peritoneum and lymph nodes, but the OCUM-12 models did not.
  • CONCLUSION: OCUM-12 and OCUM-12/Hypo may be useful for the elucidation of disease progression associated with scirrhous gastric cancer in the setting of chronic hypoxia.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Anoxia. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - OCUM-12 (CVCL_8380) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - OCUM-12/Hypo (CVCL_8381) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8322-30 [11719466.001]
  • [Cites] Curr Opin Genet Dev. 2009 Aug;19(4):338-42 [19464162.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1437-47 [14507651.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7634-7 [14633681.001]
  • [Cites] Lancet. 1971 Oct 30;2(7731):971-2 [4107917.001]
  • [Cites] Br J Radiol. 1979 Aug;52(620):650-6 [486895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1245-8 [528271.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:173-8 [6428739.001]
  • [Cites] Acta Pathol Jpn. 1986 Jan;36(1):65-83 [3962675.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3496-503 [3581084.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(2):121-31 [2157713.001]
  • [Cites] Cancer Res. 1993 Jan 15;53(2):354-61 [7678075.001]
  • [Cites] Gene. 1993 Nov 15;133(2):279-84 [8224915.001]
  • [Cites] Oncogene. 1994 Mar;9(3):963-9 [8108142.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1200-10 [7577468.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):43-54 [8521616.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2949-54 [9671416.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Jpn J Cancer Res. 2001 Jul;92(7):748-54 [11473725.001]
  • [Cites] Mol Pathol. 1998 Apr;51(2):55-61 [9713587.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1679-84 [9816116.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Oncologist. 2004;9 Suppl 5:10-7 [15591418.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):212-7 [15819718.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):334-40 [16495697.001]
  • [Cites] Curr Biol. 2006 Jun 20;16(12):1224-31 [16782014.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):965-71 [16935971.001]
  • [Cites] Placenta. 2008 Jan;29(1):51-7 [17959243.001]
  • [Cites] Am J Pathol. 2008 Feb;172(2):309-20 [18202198.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1003-11 [18281474.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4719-26 [18559518.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1387-94 [18546042.001]
  • [Cites] BMC Cancer. 2009;9:27 [19161638.001]
  • [Cites] Histopathology. 2009 Mar;54(4):442-51 [19309396.001]
  • [Cites] PLoS One. 2009;4(7):e6381 [19636430.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • (PMID = 20145613.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2833244
  •  go-up   go-down


52. Krivokapic Z, Dimtrijevic I, Markovic V, Barisic G, Antic S, Jovanovic D, Petrovic J: Salvage rectal surgery--overview. Acta Chir Iugosl; 2006;53(2):125-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrence of the disease represents the major problem in patients who undergo "curative" resection for rectal cancer, with published rate ranging from 3 to 50%.
  • In terms of potential surgical cure the best results are achieved with solitary, localized metastases.
  • The most common sites of the solitary metastases are pelvis, liver and lung, with a fairly even distribution among these three sites.
  • Other sites of the localized metastases can be peritoneum, lymph nodes, brain, bone, abdominal wall, ureter and kidney.
  • It can be stated that surgical technique directly influences local recurrence rate in patients with rectal cancer.
  • According to the results from a number of different authors 5-year survival rate after reresection is 2-13% of all patients with locally recurrent cancer, both alone and associated with distant metastases.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139900.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 51
  •  go-up   go-down


53. Miyagi M, Aoyagi K, Kato S, Shirouzu K: The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol; 2007 Feb;12(1):17-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer.
  • BACKGROUND: It has become clear in recent years that peritoneal metastasis takes place as the result of a multistep process involving attachment, invasion, proliferation, and angiogenesis.
  • The aim of the present study was to evaluate the suppressive effect of tissue inhibitor of metalloproteinase-1 (TIMP-1) gene transfer on peritoneal dissemination.
  • METHODS: We established a high-potential peritoneal metastasis cell line (MKN-45P), using the gastric cancer cell line MKN-45, and developed a peritoneal metastasis model in nude mice.
  • The TIMP-1 gene was transferred to MKN-45 or MKN-45P by adenoviral transfection, and we performed an in vitro invasion assay and an in vivo study, using the peritoneal metastasis model.
  • RESULTS: The in vitro invasion assay showed that the number of invasive cells was significantly reduced in the TIMP-1 transfected group compared with that in the non-virus group and the Lac-Z transfected group, Moreover, the in vivo studies showed that the number and the weight of the peritoneal nodes in the TIMP-1 transfected group were significantly less than those in the Lac-Z transfected group, and less than those in the non-viral group.
  • CONCLUSION: TIMP-1 demonstrated an inhibitory effect on angiogenesis, and may be worthwhile investigating for use as a future therapy for peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoviridae. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Disease Models, Animal. Female. Gene Expression Regulation, Neoplastic. Genetic Vectors. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / prevention & control. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - MKN-45P (CVCL_Y476) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380436.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


54. Voermans RP, van Berge Henegouwen MI, de Cuba E, van den Broek FJ, van Acker G, Timmer R, Fockens P: Randomized, blinded comparison of transgastric, transcolonic, and laparoscopic peritoneoscopy for the detection of peritoneal metastases in a human cadaver model. Gastrointest Endosc; 2010 Nov;72(5):1027-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, blinded comparison of transgastric, transcolonic, and laparoscopic peritoneoscopy for the detection of peritoneal metastases in a human cadaver model.
  • OBJECTIVE: To compare transgastric peritoneoscopy (TGP) and transcolonic peritoneoscopy (TCP) to LAP, pairwise, in a randomized, blinded (to location and number of beads) human cadaver model with simulated peritoneal metastases.
  • DESIGN: Metastases were simulated by 2.5-mm, color-coded beads, which were placed into the peritoneal cavity via an open approach.
  • In previous porcine experiments, LAP resulted in a yield of 95%.
  • CONCLUSION: In this prospective, blinded, comparative trial in a human cadaver model, TCP was comparable to LAP in detecting simulated metastases.
  • [MeSH-major] Laparoscopy / methods. Natural Orifice Endoscopic Surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [CommentIn] Gastrointest Endosc. 2010 Nov;72(5):1034-5 [21034903.001]
  • (PMID = 20850736.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Valenza V, Di Giuda D, Perotti G, Carbone A: Diffuse peritoneal metastases from primary colon cancer demonstrated by Tc-99m-labeled red blood cell scintigraphy. Clin Nucl Med; 2005 Apr;30(4):286-8
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse peritoneal metastases from primary colon cancer demonstrated by Tc-99m-labeled red blood cell scintigraphy.
  • An 80-year-old man, who underwent complex abdominal surgery for left colon cancer 2 years earlier, was hospitalized because of severe anemia and recurrent episodes of melena.
  • Abdominal ultrasonographic examination and computed tomographic scan failed to detect tumor recurrence or metastatic lesions but moderate ascites was found.
  • Tc-99m red blood cell scintigraphy was performed and disclosed a potential site of intestinal hemorrhage: both dynamic and static images showed a slight but diffuse and persistent uptake of Tc-99m erythrocytes in the entire abdomen with no clear evidence of a site of active bleeding.
  • These findings suggested diffuse peritoneal micrometastases, which were confirmed at autopsy.
  • [MeSH-major] Colonic Neoplasms / radionuclide imaging. Erythrocytes / radionuclide imaging. Peritoneal Neoplasms / radionuclide imaging. Peritoneal Neoplasms / secondary. Technetium

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764895.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 7440-26-8 / Technetium
  •  go-up   go-down


56. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, Kenzaki K, Miyoshi T, Kondo K, Bando Y, Ohnishi Y, Tangoku A: Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer; 2009 Aug 15;125(4):952-60
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo.
  • A new animal model of esophageal cancer causing tumor colonization of the peritoneal cavity and producing bloody ascites was made by injecting YES-2 cells into the peritoneal cavity of a severe combined immunodeficiency mouse.
  • In this model, 5-fluorouracil inhibited colonization of tumor cells in the peritoneum.
  • The addition of JAE to 5-fluorouracil augmented the suppression of experimental metastasis of the peritoneum.
  • The numbers of peritoneal nodules of more than 2 mm in diameter in mice treated with 5-fluorouracil and JAE were less than those in mice treated with 5-fluorouracil alone or JAE alone.
  • These results suggest that triterpenes, especially JAE, are effective supplements for enhancing the chemotherapeutic effect of 5-fluorouracil on esophageal cancer.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Cell Proliferation / drug effects. Esophageal Neoplasms / drug therapy. Fluorouracil / pharmacology. Peritoneal Neoplasms / drug therapy. Triterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19462449.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Preparations; 0 / Triterpenes; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


57. Cabourne EJ, Roberts G, Goldin R, Ryder T, Mobberly M, Ziprin P: Investigation of tumor-peritoneal interactions in the pathogenesis of peritoneal metastases using a novel ex vivo peritoneal model. J Surg Res; 2010 Dec;164(2):e265-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of tumor-peritoneal interactions in the pathogenesis of peritoneal metastases using a novel ex vivo peritoneal model.
  • BACKGROUND: Peritoneal metastasis occurs in up to 30% of patients with gastric cancer.
  • The aim of this experimental study is to develop and validate a novel ex vivo model of the human peritoneum to better identify factors involved in the development of peritoneal metastasis in order to improve its management and prognosis.
  • METHODS: Peritoneal discs harvested from hernia sacs obtained at inguinal hernia surgery were suspended in media using Teflon rings.
  • Modulation of tumor cell adhesion to peritoneum after exposure to heparin was assessed using a fluorometric adhesion assay.
  • Mesothelial cell loss at 48 h was demonstrated by LM and SEM, confirming peritoneal viability for at least 24 h after tissue harvesting.
  • Zymography confirmed increased MMP2 and -9 activities in tumor cells and peritoneal tissue during co-culture compared with controls, and heparin significantly reduced tumor cell adherence (P = 0.04), as observed in published in vivo models.
  • CONCLUSION: A validated complete model of peritoneum was developed that has shown potential to determine realistic mechanisms of peritoneal metastasis.
  • [MeSH-major] Hernia, Inguinal / surgery. Neoplasm Metastasis / pathology. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cell Adhesion. Cell Culture Techniques / methods. Cell Line, Tumor. Cell Survival. Coculture Techniques. Humans. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Microscopy, Electron, Scanning / methods. Peritoneum / pathology. Peritoneum / surgery. Peritoneum / ultrastructure. Prognosis. Stomach Neoplasms / enzymology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20951998.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


58. Koppe MJ, Oyen WJ, Bleichrodt RP, Hendriks T, Verhofstad AA, Goldenberg DM, Boerman OC: Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Immunol Immunother; 2006 Jan;55(1):47-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
  • The aim of this study was to investigate whether the efficacy of radioimmunotherapy (RIT) using 131I-labeled anti-CEA monoclonal antibody MN-14 could be enhanced by co-administration of the selective COX-2 inhibitor Parecoxib in mice with small volume (1-3 mm) peritoneal carcinomatosis of colonic origin.
  • Second, the influence of Parecoxib (1.0 or 5.0 mg/kg) on the biodistribution of 125I-MN-14 was assessed.
  • RIT alone significantly delayed the growth of the intraperitoneal xenografts resulting in a median survival of 87 days (P<0.0001).
  • CONCLUSION: The COX-2 inhibitor Parecoxib does not enhance the therapeutic efficacy of RIT of experimental small volume peritoneal carcinomatosis of colonic origin.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Colonic Neoplasms / pathology. Cyclooxygenase Inhibitors / therapeutic use. Isoxazoles / therapeutic use. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868166.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase Inhibitors; 0 / Iodine Radioisotopes; 0 / Isoxazoles; 9TUW81Y3CE / parecoxib
  •  go-up   go-down


59. Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H: Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res; 2007 Apr 15;67(8):3809-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody.
  • Optical probes that yield high target-to-background ratios are necessary to detect microfoci of cancer that would otherwise escape detection with white light imaging.
  • Following this, a second agent, neutravidin-BODIPY-FL fluorescent conjugate, is given and binds to the previously targeted antibody, resulting in an approximately 10-fold amplification of the optical fluorescence signal, leading to high tumor-to-background ratios.
  • Spectral fluorescence imaging was done in a mouse model of peritoneal metastasis using a HER1-overexpressing cell line (A431) after pretargeting with biotinylated cetuximab and 3 h after administration of neutravidin-conjugated BODIPY-FL.
  • Both aggregated tumors as well as small cancer implants were clearly visualized in vivo.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Avidin / metabolism. Fluorescent Dyes / metabolism. Immunoconjugates / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17440095.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Boron Compounds; 0 / Fluorescent Dyes; 0 / Immunoconjugates; 0 / neutravidin; 1405-69-2 / Avidin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


60. Wang X, Wang E, Kavanagh JJ, Freedman RS: Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med; 2005 Jun 21;3:25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer, the coagulation pathway, and inflammation.
  • Epithelial ovarian cancer (EOC) represents the most frequent cause of death in the United States from a cancer involving the female genital tract.
  • Contributing to the overall poor outcome in EOC patients, are the metastases to the peritoneum and stroma that are common in this cancer.
  • This study showed a number of genes with significantly altered expression in the pelvic peritoneum and stroma, and in the vicinity of EOC implants.
  • In addition to promoting the formation of blood clots, coagulation factors exhibit many other biologic functions as well as tumorigenic functions, the later including tumor cell proliferation, angiogenesis, invasion, and metastasis.
  • In a recent study we conducted, we found that factor XII, factor XI, and several coagulation regulatory proteins, including heparin cofactor-II and epithelial protein C receptor (EPCR), were also upregulated in the peritoneum of EOC.
  • In this review, we summarize evidence in support of a role for these factors in promoting tumor cell progression and the formation of ascites.
  • We also discuss the different roles of coagulation factor pathways in the tumor and peritumoral microenvironments as they relate to angiogenesis, proliferation, invasion, and metastasis.
  • Since inflammatory responses are another characteristic of the peritoneum in EOC, we also discuss the linkage between the coagulation cascade and the cytokines/chemokines involved in inflammation.
  • Lastly, we review findings regarding the inflammatory process yielded by certain clinical trials of agents that target members of the coagulation cascade in the treatment of cancer.
  • Current data suggest that disrupting certain elements of the coagulation and inflammation processes in the tumor microenvironment could be a new biologic approach to cancer therapeutics.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1989 Oct 1;49(19):5448-58 [2475250.001]
  • [Cites] Thromb Haemost. 1993 Apr 1;69(4):366-9 [8497849.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1374-83 [15178554.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4427-36 [15240533.001]
  • [Cites] Thromb Res. 2000 Dec 1;100(5):443-51 [11150588.001]
  • [Cites] Thromb Haemost. 2001 Feb;85(2):356-61 [11246560.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):10952-62 [11278329.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):570-6 [11297250.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2960-8 [11358513.001]
  • [Cites] Ann N Y Acad Sci. 2001;936:426-37 [11460496.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2372-9 [11489815.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7811-8 [11691797.001]
  • [Cites] J Gastroenterol. 2001 Dec;36(12):848-50 [11777214.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):213-9 [11805133.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):16081-7 [11850418.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):389-95 [11875705.001]
  • [Cites] Am J Hematol. 2002 Apr;69(4):247-54 [11921018.001]
  • [Cites] Int J Oncol. 2002 May;20(5):921-8 [11956584.001]
  • [Cites] Clin Exp Metastasis. 2002;19(2):135-44 [11964077.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27065-72 [12019261.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1880-2 [12052963.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1535-42 [12110501.001]
  • [Cites] Curr Opin Hematol. 2002 Sep;9(5):401-6 [12172458.001]
  • [Cites] Nat Med. 2003 Mar;9(3):338-42 [12563316.001]
  • [Cites] Thromb Haemost. 2003 Feb;89(2):405-7 [12574822.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L566-77 [12618418.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):346-55 [12645335.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1503-13 [12707033.001]
  • [Cites] Trends Immunol. 2004 Oct;25(10):536-42 [15364056.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):372-8 [15455382.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7361-9 [15492257.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2004 Sep;25(9):523-7 [15569528.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):113-22 [15671535.001]
  • [Cites] J Biol Chem. 1988 Dec 5;263(34):18205-12 [2848029.001]
  • [Cites] Mol Cell Biol. 1988 Dec;8(12):5588-92 [2854203.001]
  • [Cites] Nat Med. 2004 May;10(5):502-9 [15098027.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2766-70 [15102682.001]
  • [Cites] Crit Care Med. 2004 May;32(5 Suppl):S298-301 [15118534.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2761-5 [15148272.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2004 Mar;25(3):143-6 [15182581.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):80-5 [15262123.001]
  • [Cites] Mol Cancer Res. 2004 Jul;2(7):395-402 [15280447.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):725-31 [15305183.001]
  • [Cites] Clin Biochem. 2004 Sep;37(9):823-9 [15329323.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 22;323(3):1084-90 [15381110.001]
  • [Cites] J Thromb Haemost. 2004 Oct;2(10):1713-9 [15456480.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):333-45 [15488757.001]
  • [Cites] Thromb Res. 2004;114(5-6):321-7 [15507261.001]
  • [Cites] FEBS Lett. 2004 Nov 5;577(1-2):175-80 [15527781.001]
  • [Cites] Oncology. 2004;67(2):166-73 [15539922.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4650-60 [7876236.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1006-16 [7906563.001]
  • [Cites] J Biol Chem. 1994 Oct 21;269(42):26486-91 [7929370.001]
  • [Cites] Biochem J. 1994 Oct 1;303 ( Pt 1):227-31 [7945245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3353-7 [8159751.001]
  • [Cites] Thromb Haemost. 1993 Jul 1;70(1):68-71 [8236117.001]
  • [Cites] J Immunol Methods. 1994 Jan 3;167(1-2):145-60 [8308273.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 4;85(15):1225-30 [8331683.001]
  • [Cites] Haemostasis. 1993 Mar;23 Suppl 1:103-6 [8388347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6934-8 [2169613.001]
  • [Cites] J Biol Chem. 1990 Apr 15;265(11):6092-7 [2318847.001]
  • [Cites] J Cell Biol. 1985 Sep;101(3):880-6 [2411738.001]
  • [Cites] Clin Exp Metastasis. 1989 Mar-Apr;7(2):187-99 [2465862.001]
  • [Cites] Blood. 2004 Jul 15;104(2):397-401 [15031212.001]
  • [Cites] Maturitas. 2004 Apr 15;47(4):305-14 [15063484.001]
  • [Cites] J Cell Biol. 1996 Apr;133(2):293-304 [8609163.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):17629-34 [8663424.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1384-90 [8435814.001]
  • [Cites] Nat Med. 1996 Feb;2(2):209-15 [8574967.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1407-21 [8623913.001]
  • [Cites] Am J Med. 1996 Mar;100(3):269-77 [8629671.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29034-42 [8910556.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1723-34 [9137096.001]
  • [Cites] Circulation. 1997 Jul 15;96(2):605-13 [9244233.001]
  • [Cites] Nature. 1998 Feb 5;391(6667):591-4 [9468137.001]
  • [Cites] J Leukoc Biol. 1998 Mar;63(3):373-9 [9500526.001]
  • [Cites] J Exp Med. 1998 Apr 6;187(7):1029-35 [9529319.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):262-4 [9641227.001]
  • [Cites] Clin Exp Immunol. 1998 May;112(2):172-80 [9649178.001]
  • [Cites] Trends Cell Biol. 1998 Sep;8(9):359-64 [9728397.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1089-94 [9815898.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):472-7 [10027315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-5 [10051638.001]
  • [Cites] BMJ. 1999 Jun 12;318(7198):1571-2 [10364099.001]
  • [Cites] Blood. 1999 Jul 15;94(2):632-41 [10397730.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21349-54 [10409695.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1663-9 [10511594.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):600-8 [10653875.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2586-92 [10753838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5255-60 [10805786.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1953-8 [10874063.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):164-70 [10901365.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4719-24 [10987275.001]
  • [Cites] Semin Thromb Hemost. 2000;26 Suppl 1:69-77 [11011810.001]
  • [Cites] Thromb Haemost. 2000 Oct;84(4):657-63 [11057866.001]
  • [Cites] Circulation. 2001 Jan 2;103(1):125-32 [11136697.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5933-40 [11479236.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1797-805 [11696440.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):295-300 [11782391.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1646-50 [11861279.001]
  • [Cites] Semin Thromb Hemost. 2002 Feb;28(1):79-87 [11885028.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1108-14 [11948121.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24584-93 [11978786.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):201-7 [12023851.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):930-6 [12083498.001]
  • [Cites] J Allergy Clin Immunol. 2002 Jul;110(1):139-46 [12110833.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):807-11 [12591730.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1710-20 [12738725.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2997-3000 [12782609.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):255-7 [12807235.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34548-54 [12821662.001]
  • [Cites] Microcirculation. 2003 Jun;10(3-4):335-50 [12851650.001]
  • [Cites] J Thromb Haemost. 2003 Jul;1(7):1343-8 [12871267.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):948-55 [12878203.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):237-45 [14568692.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003 Dec;11(6):579-82 [14706138.001]
  • [Cites] Circulation. 2004 Feb 3;109(4):481-6 [14744972.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):678-85 [14966091.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3029-37 [15070680.001]
  • [Cites] Thromb Haemost. 2004 May;91(5):905-11 [15116250.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1476 [1351142.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):237-48 [1423816.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11832-6 [1465406.001]
  • [Cites] Biochemistry. 1991 Feb 5;30(5):1350-7 [1671335.001]
  • [Cites] Thromb Haemost. 1991 Jul 12;66(1):67-79 [1833852.001]
  • [Cites] J Clin Invest. 1991 Jan;87(1):229-36 [1845869.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4382-5 [1852005.001]
  • [Cites] J Biol Chem. 1990 Jun 5;265(16):9302-7 [1971626.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):704-9 [1985958.001]
  • [Cites] Blood. 1990 Apr 15;75(8):1673-8 [2139349.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):276-84 [8903466.001]
  • [Cites] J Androl. 1996 Nov-Dec;17(6):659-65 [9016396.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):411-8 [9218519.001]
  • [Cites] Blood. 1998 Jan 15;91(2):725-7 [9427734.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1372-8 [9525979.001]
  • [Cites] J Immunol. 1998 May 15;160(10):5130-5 [9590265.001]
  • [Cites] Nat Med. 1998 Aug;4(8):909-14 [9701242.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3694-700 [9808563.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):401-6 [10027305.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):438-42 [10209959.001]
  • [Cites] Ann Intern Med. 1999 May 18;130(10):800-9 [10366369.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23969-76 [10446165.001]
  • [Cites] Thromb Haemost. 1999 Aug;82(2):947-52 [10605808.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):874-82 [10712416.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2268-78 [10873077.001]
  • [Cites] Blood. 2000 Jul 1;96(1):170-5 [10891447.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):258-64 [11001069.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4697-703 [11035113.001]
  • [Cites] Med Hypotheses. 2000 Dec;55(6):470-3 [11090292.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11199-203 [11278252.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2031-41 [11395381.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2746-51 [15265791.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Cancer. 1984 May 15;53(10):2046-52 [6322957.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1320-7 [7521887.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):376-85 [7529135.001]
  • [Cites] Thromb Haemost. 1995 Mar;73(3):405-12 [7545318.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):303-8 [7657523.001]
  • [Cites] J Biol Chem. 1993 Jan 5;268(1):421-9 [7678000.001]
  • [Cites] Am J Physiol. 1993 May;264(5 Pt 1):C1302-7 [7684562.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2391-6 [7738202.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):369-75 [7812970.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):198-210 [7834119.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1708-15 [12738672.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3130-7 [12789289.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):44-50 [12821340.001]
  • [Cites] J Endotoxin Res. 2003;9(3):192-8 [12831462.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3224-31 [12869501.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3958-65 [12873991.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):67-79 [12892714.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3119-26 [12915603.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1069-77 [14525759.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1311-8 [14576048.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):9032-41 [14695222.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):410-7 [14724569.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):686-92 [14760385.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1990-9 [14966279.001]
  • (PMID = 15969748.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1182397
  •  go-up   go-down


61. Asai K, Fujita T, Nakamura Y, Tokuda E, Hiyoshi M, Aoki F, Sugizaki K, Masaki Y: [A case of multiple hepatic and peritoneal metastases from colon cancer responding to oral UFT+leucovorin chemotherapy]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1959-61
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple hepatic and peritoneal metastases from colon cancer responding to oral UFT+leucovorin chemotherapy].
  • A 57-year-old woman underwent right hemicolectomy (D3) due to transverse colon cancer with multiple liver and peritoneal metastasis.
  • After 6 months, the multiple liver metastases completely disappeared without any adverse reaction.
  • This case suggests the usefulness of oral UFT+Leucovorin for progressive recurrent colorectal cancer as home chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282735.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin; 1-UFT protocol
  •  go-up   go-down


62. Imamura H, Kishimoto T, Kawabata R, Furukawa H, Fukunaga M, Ohzato H, Miyanishi K, Yamamoto T, Miwa H: [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2490-2
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with bilateral ovarian metastasis after gastrectomy performed ovarian resection].
  • The patient was a 51-year-old female, who underwent radical surgery for cancer of remnant stomach in May 2006 (f-T4N0M0P0H0CY0, por 2, Stage IIIA, Cur B).
  • Bilateral ovarian resection was performed in March 2009 for bilateral ovarian metastasis, so called "Krukenberg tumor" with peritoneal dissemination detected with CT scan after one-year adjuvant chemotherapy with S-1 (80 mg/m2, 4 weeks on and 2 weeks off).
  • As of June 2010, she is alive and maintain her status quo after 6 courses of S-1 plus CDDP combination therapy (S-1 80 mg/m2, 3 weeks on, CDDP 60 mg/m2, started at day 8, ended 35 days later) followed by S-1 for residual peritoneal dissemination detected at operation.
  • In ovary metastasis of gastric cancer, even if accompanied by peritoneum metastasis, ovarian resection as a reduction surgery followed by chemotherapy may improve survival.
  • [MeSH-major] Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224616.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


63. Wang R, Zhang T, Ma Z, Wang Y, Cheng Z, Xu H, Li W, Wang X: The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecol Oncol; 2010 Jun;117(3):460-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer.
  • OBJECTIVES: Pathological studies have indicated that the peritoneum of epithelial ovarian cancer (EOC) patients exhibits characteristics of chronic inflammation like peritonitis.
  • Abundant macrophage infiltration and increased expression of coagulation factor XII (FXII) have been observed in the peritoneum of EOC patients.
  • The aim of this study is to determine how the interaction between FXII and monocyte/macrophages (MO/MAs) contributes to EOC cell invasion and metastasis of the peritoneum.
  • CONCLUSIONS: FXII may facilitate EOC cell metastasis by transforming MO/MAs toward tumor-associated macrophage-like cells.
  • [MeSH-major] Factor XII / immunology. Macrophages / immunology. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Antigens, CD / biosynthesis. Cell Line, Tumor. Cells, Cultured. Cytokines / biosynthesis. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Phagocytosis. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20233624.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / Transcription Factors; 9001-30-3 / Factor XII
  •  go-up   go-down


64. Dasari BV, Loan W, Carey DP: Spilled gallstones mimicking peritoneal metastases. JSLS; 2009 Jan-Mar;13(1):73-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spilled gallstones mimicking peritoneal metastases.
  • CASE REPORT: We report a case of spilled gallstones mimicking peritoneal metastases on radiological investigations; diagnosis was confirmed by diagnostic laparoscopy.
  • When all the stones cannot be retrieved, it should be documented in the patient's medical records to avoid delay in the diagnosis of late complications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1441-5 [10789809.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1226-32 [11984670.001]
  • [Cites] Surg Endosc. 2004 Aug;18(8):1200-7 [15457378.001]
  • [Cites] Am J Surg. 2007 Jan;193(1):73-8 [17188092.001]
  • [Cites] Surg Endosc. 1998 Apr;12(4):305-9 [9543518.001]
  • [Cites] Surg Endosc. 1999 Nov;13(11):1099-102 [10556446.001]
  • [Cites] HPB Surg. 1998;11(2):105-8; discuss 108-9 [9893240.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):450-2 [15820459.001]
  • [Cites] J Gastrointest Surg. 1997 Jan-Feb;1(1):85-90; discussion 90-1 [9834334.001]
  • [Cites] Surg Endosc. 1992 Mar-Apr;6(2):84 [1344590.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):564-7 [16447096.001]
  • [Cites] Eur J Surg. 1998 Jun;164(6):425-31 [9696443.001]
  • (PMID = 19366546.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015906
  •  go-up   go-down


65. Park JS, Kim L, Kim CH, Bang BW, Lee DH, Jeong S, Shin YW, Kim HG: Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon. Gut Liver; 2010 Mar;4(1):122-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large-cell neuroendocrine carcinoma of the colon is a rare entity with a prognosis that is usually poor due to the high likelihood of early metastasis.
  • A 61-year-old man had surgery for colon cancer of the transverse colon and cecum.
  • Cancer metastasis was found in the peritoneum section of the small bowel.
  • This is the first case of a synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2008 Jan;100(1):11-6 [18358055.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):325-7 [18064472.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):491-505 [16183523.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1049-51 [15154621.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • (PMID = 20479925.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871610
  • [Keywords] NOTNLM ; Chemotherapy / Colonic neoplasms / Multiple primary neoplasms / Neuroendocrine carcinoma
  •  go-up   go-down


66. Matsutani T, Suzuki S, Mizutani T, Miyamoto M, Maruyama H, Yokoyama T, Yanagi K, Matsushita A, Kashiwabara M, Matsuda A, Nishi Y, Arai H, Sasajima K, Tajiri T: [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1193-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
  • A 75-year-old man with advanced gastric cancer underwent distal gastrectomy with lymph node dissection(D1)and Roux-en Y reconstruction.
  • Abdominal computed tomography(CT)2 months postoperatively showed multiple liver metastases and ascites.
  • We then conducted tailored S-1/CPT-11 as second-line chemotherapy(S-1 80 mg/body weight on days 1-5 and 8-12, CPT-11 60 mg/body weight on days 1 and 8).
  • After 5 courses of this therapy, CT showed that the liver metastases and ascites had disappeared, leading to a complete response(CR).
  • Adverse events in tailored S-1/CPT-11 combination therapy are mild and tolerable, making this regimen a potential therapeutic strategy for patients with advanced or recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Liver Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Gastroscopy. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633261.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


67. Zhi K, Shen X, Zhang H, Bi J: Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers. J Exp Clin Cancer Res; 2010;29:66
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers.
  • BACKGROUND: The prognosis of gastric cancer patients is difficult to predict because of defects in establishing the surgical-pathological features.
  • Cancer-associated fibroblasts (CAFs) have been found to play prominent role in promoting tumor growth, invasion and metastasis.
  • Thus raises the hypothesis that the extent of CAFs prevalence may help to establish the prognosis of gastric cancer patients.
  • The extent of CAFs' prevalence was graded according to immunochemical staining, and correlation was further analyzed between CAFs' prevalence and other tumor characteristics which may influence the prognosis of gastric cancer patients.
  • RESULTS: Nearly 80 percent of normal gastric tissues were negative or weak positive for CAFs staining, while more than 60 percent of gastric cancer tissues were moderate or strong positive for CAFs staining.
  • Realtime-PCR results also showed significant elevated expression of FAP, SDF-1 and TGF-beta1 in gastric cancer tissues compared to normal gastric tissues.
  • Further analysis showed that CAFs' prevalence was correlated with tumor size, depth of the tumor, lymph node metastasis, liver metastasis or peritoneum metastasis.
  • CONCLUSIONS: Reactive cancer associated fibroblasts (CAFs) were frequently accumulated in gastric cancer tissues, and the prevalence of CAFs was correlated with tumor size, depth of the tumor and tumor metastasis, thus give some supports for establishing the prognosis of the gastric cancer patients.
  • [MeSH-major] Fibroblasts / pathology. Liver Neoplasms / secondary. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Actins / genetics. Actins / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Calcium-Binding Proteins / genetics. Calcium-Binding Proteins / metabolism. Case-Control Studies. Collagen Type I / genetics. Collagen Type I / metabolism. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6021-5 [12414622.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Am J Pathol. 1981 Sep;104(3):206-16 [6170230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9 [2402505.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):909-15 [8217606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61 [7911242.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):393-405 [7615639.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Mol Diagn Ther. 2006;10(6):345-52 [17154651.001]
  • [Cites] Arch Biochem Biophys. 2007 Jan 15;457(2):177-86 [17174263.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1736-41 [17363526.001]
  • [Cites] Am Surg. 2007 Apr;73(4):359-66 [17439029.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4869-77 [17495323.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Sep;22(9):1435-42 [17573829.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Biochemistry. 2008 Jan 22;47(3):1076-86 [18095711.001]
  • [Cites] Nat Genet. 2008 May;40(5):650-5 [18408720.001]
  • [Cites] Ultrastruct Pathol. 2008 May-Jun;32(3):89-96 [18570153.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19864-71 [18495668.001]
  • [Cites] Pancreas. 2008 Aug;37(2):154-8 [18665076.001]
  • [Cites] Trends Genet. 2009 Jan;25(1):30-8 [19054589.001]
  • [Cites] J Pathol. 2009 Jun;218(2):192-200 [19224540.001]
  • [Cites] Endocr Relat Cancer. 2009 Sep;16(3):663-73 [19556286.001]
  • [Cites] Digestion. 2009;80(3):148-58 [19713703.001]
  • [Cites] J Korean Med Sci. 2009 Dec;24(6):1158-64 [19949675.001]
  • [Cites] J Clin Invest. 2009 Dec;119(12):3613-25 [19920354.001]
  • [Cites] Med Clin (Barc). 2010 Feb 6;134(3):123-6 [19944435.001]
  • [Cites] Semin Cell Dev Biol. 2010 Feb;21(1):19-25 [19857592.001]
  • [Cites] Mol Ther. 2001 Feb;3(2):149-59 [11237671.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • (PMID = 20529313.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Calcium-Binding Proteins; 0 / Collagen Type I; 0 / FSP1 protein, human; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC2892440
  •  go-up   go-down


68. Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, Dimopoulos MA, Bamias A: Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. Int J Gynecol Cancer; 2009 Nov;19(8):1329-34
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
  • INTRODUCTION: The presence of CD3(+) tumor-infiltrating lymphocytes (TILs) has been found to correlate with improved survival in epithelial ovarian cancer, but the association of TIL subpopulations with clinical outcome remains controversial.
  • We performed a prospective analysis of TIL subpopulations from patients with epithelial ovarian cancer and their activation status and studied their association with prognosis.
  • CONCLUSIONS: The presence of regulatory T cells and activated CD4(+) cells within the tumor microenvironment is associated with improved overall and progression-free survival in patients with ovarian cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphocytes, Tumor-Infiltrating / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. T-Lymphocytes / pathology. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Aged, 80 and over. Antigens, CD3 / metabolism. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Prognosis. Prospective Studies. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009885.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Organoplatinum Compounds; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


69. Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H, Yasui W: Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif; 2009 Feb;42(1):110-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV enhances peritoneal metastasis in gastric carcinomas.
  • OBJECTIVES: The role of Regenerating (Reg) IV on peritoneal metastasis was examined in gastric cancer using.
  • MATERIAL AND METHODS: Reg IV-transfected human gastric cancer cells (MKN28-R1, MKN28-R2, TMK1-R1), control transfectants (MKN28-R0, TMK1-R0), and REG4-knocked down MKN45 cells were examined in in vitro and in nude mice peritoneal metastasis models.
  • In mice models, increased number and size of peritoneal tumors and decreased apoptosis were found in Reg IV-transfectants, whereas those were abrogated by the knockdown cells.
  • Levels of Reg IV protein in peritoneal lavage fluids increased in Reg IV-transfectants inoculated mice, but decreased in Reg IV-knockdown cell inoculated mice.
  • In metastasized human gastric cancers, Reg IV positivity in peritoneum-metastasis cases was higher than those in negative cases.
  • Reg IV was detected in peritoneal lavage fluids from human gastric cancer patients, in whose lavages keratin mRNA was detected by reverse transcriptase-polymerase chain reaction.
  • Collectively, Reg IV might accelerate peritoneal metastasis in gastric cancer.
  • Reg IV in lavage fluids might be a good marker for peritoneal metastasis.
  • [MeSH-major] Lectins, C-Type / physiology. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology


70. Lin CC, Liang HP, Lee HS, Huang GT, Yang PM, Ho MC, Lee PH, Tsang YM, Chen DS, Sheu JC, Chen CH: Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol; 2009 May;24(5):815-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis.
  • BACKGROUND AND AIM: Peritoneal metastasis is an uncommon manifestation of hepatocellular carcinoma (HCC).
  • The aim of the present paper was to investigate the characteristics and survival of HCC patients with peritoneal metastases.
  • METHODS: From January 1985 to December 2004, we retrospectively reviewed the records of 53 Taiwanese HCC patients with peritoneal metastases.
  • RESULTS: Peritoneal metastases were detected at the time of HCC diagnosis (synchronously) in 10 patients and after the initial therapy for the primary tumors (metachronously) in 43 patients.
  • The mean time for development of the metachronous peritoneal metastases was similar whether the primary cancer was treated with surgery (24 months) or transarterial chemoembolization (22.2 months).
  • The single patient whose primary cancer was treated with supportive care alone developed peritoneal metastasis only 7.5 months after detection of the primary cancer.
  • Surgical resection of the peritoneal metastases was possible in two-thirds of the 43 metachronous patients.
  • The median survival for those who received surgery for these metastases was 12.5 months vs. 2.1 months for those without surgery (P = 0.0013).
  • CONCLUSIONS: Peritoneal metastases of HCC are rare and can occur synchronously or metachronously.
  • Though increased long-term survival was found in patients who had surgical removal of peritoneal metastases, the main determinant of better survival is Child-Pugh grade.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / mortality. Liver Neoplasms / pathology. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemoembolization, Therapeutic. Female. Hepatectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Taiwan / epidemiology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19655437.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


71. Bamba T, Kanda T, Ohashi M, Hanyu T, Sakamoto K, Ishikawa T, Yajima K, Makino S, Tanabe T, Kosugi S, Hatakeyama K: [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1695-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
  • Between 1998 and 2004, seven patients who had histologically proven gastric adenocarcinoma with peritoneal metastases underwent palliative gastrectomy at Niigata University Medical Hospital.
  • For residual peritoneal tumors, 100 mg/body of CDDP diluted with distilled water was intraperitoneally administered to the patients before closure of abdominal wall and was drained 30 to 60 minutes after administration.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Female. Fluorouracil / administration & dosage. Humans. Hypotonic Solutions. Infusions, Parenteral. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Seeding

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315912.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypotonic Solutions; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


72. Kimura Y, Taniguchi H, Yano H, Miyazaki S, Nakamura H, Danno K, Kanoh T, Ohnishi T, Tono T, Nakano Y, Kagawa K, Monden T, Imaoka S: [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2499-501
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastasis from gastric cancer treated with stereotactic radiation therapy].
  • We report a case of liver metastasis from gastric cancer that was effectively controlled with stereotactic radiation therapy (SRT).
  • A 77-year-old man underwent total gastrectomy, splenectomy, cholecystectomy and D2 dissection in February 2007 for type 3 gastric cancer in the upper third area that was diagnosed well to moderately differentiated adenocarcinoma and Stage II (T3 (SE) N0 H0 P0 CY0 M0).
  • He suffered from the liver and peritoneal metastases with ascites in December 2007, so S-1 was administered.
  • Ascites was disappeared, but liver metastasis was enlarged.
  • Therefore, SRT (total of 52.8 Gy per 4 fractions) was performed for the liver metastasis.
  • It is thought that SRT is one of effective treatments for liver metastasis from gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Radiosurgery. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224619.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Maksimović S: [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. Med Arh; 2007;61(1):26-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mucinous adenocarcinoma is one of the histological subtypes of colorectal cancer.
  • Frequently are more advanced at diagnosis and have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • RESULTS: The mucinous adenocarcinoma patients compared to patients with nonmucinous adenocarcinoma patients were found to be younger (p= 0,001), have more lymph node metastases (46,15% vs. 38,31%, p=0,0053), more peritoneal dissemination (20,51% vs. 5,1%, p <0,0001), greater frequency of advanced stage disease (p= 0,0006), lower rate of curative resection (76,3% vs. 84,9%, p=0,0045), and lower overall 5-year survival rates (39% vs. 60,3%, p=0,0002.
  • DISCUSSION: Conflicting results are found in the published literature regarding the relationship between mucinous colorectal cancer and survival.
  • Indeed, these series studied prognosis from initial diagnosis, generally in patients treated with surgery alone, and did not specifically address outcomes in patients treated with chemotherapy.
  • Mucinous tumors were associated with a higher proportion of patients with nodal metastases and peritoneal metastases, while the most common site of metastases for patients with non-mucinous histology was the liver.
  • A higher proportion of peritoneal metastases in patients with mucinous CRC were also reported in previous studies.
  • Conversely, in the present study, the other main characteristics of patients, such age, performance status, primary tumor side, baseline CEA level and number of metastasis sites, were comparable in cases and controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582971.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 25
  •  go-up   go-down


74. Herman P, Machado MA, Montagnini AL, D'Albuquerque LA, Saad WA, Machado MC: Selected patients with metastatic melanoma may benefit from liver resection. World J Surg; 2007 Jan;31(1):171-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selected patients with metastatic melanoma may benefit from liver resection.
  • BACKGROUND: In the last few years there has been expanding use of hepatic resection for non-colorectal metastases.
  • The purpose of this study is to evaluate the experience of liver resection for patients with metastatic melanoma.
  • METHODS: Eighteen patients with metastatic melanoma were explored for possible surgical resection.
  • RESULTS: Liver resection was performed in 10 patients; 8 out of 18 presented with irresectable tumors and/or peritoneal metastases and were not operated.
  • CONCLUSIONS: Resection of liver metastases from melanoma in a selected group of patients may increase survival.
  • [MeSH-major] Eye Neoplasms / pathology. Hepatectomy. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Melanoma / secondary. Patient Selection. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17171491.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


75. Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging; 2006 Sep-Oct;31(5):568-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.
  • BACKGROUND: Preoperative chemoradiation can potentially improve outcomes in patients with pancreatic cancer.
  • This study addresses its effect on staging pancreatic cancer with multidetector computed tomography (MDCT).
  • METHODS: Fifty-five patients underwent a dual-phase MDCT pancreas protocol for proved pancreatic cancer.
  • Three radiologists independently reviewed images to assess for locally advanced disease, liver and peritoneal metastases on baseline studies of all 55 patients, and on follow-up preoperative studies for the 16 patients receiving preoperative therapy.
  • CONCLUSION: The negative predictive value for MDCT for identifying unresectable pancreatic cancer in the setting of preoperative therapy is comparable to that reported in the absence of neoadjuvant therapy.
  • [MeSH-major] Neoplasm Staging / methods. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465578.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Triiodobenzoic Acids; 87771-40-2 / ioversol
  •  go-up   go-down


76. Shibata N, Eto TA, Hotokezaka M, Iwamura T, Chijiiwa K: [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1159-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
  • A 43-year-old woman who complained of abdominal fullness, appetite loss, and constipation was diagnosed as unresectable advanced schirrhous gastric cancer with left supra-clavicular lymph node metastases, massive ascites, rectal stenosis, and bilateral hydronephrosis due to peritoneal metastases.
  • After 3 courses, computed tomography showed markedly reduced supra-clavicular lymph node metastases and no ascites.
  • The biweekly paclitaxel and TS-1 chemotherapy may well be an effective treatment for advanced schirrhous gastric cancer with carcinomatous peritonitis.
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites. Constriction, Pathologic. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritonitis / etiology. Pyridines / administration & dosage. Rectal Diseases / etiology. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


77. Tuttle TM, Zhang Y, Greeno E, Knutsen A: Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol; 2006 Dec;13(12):1627-32
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of our study was to determine the toxicity and quality of life for patients with peritoneal metastases after cytoreductive surgery (CS) plus hyperthermic intraperitoneal chemotherapy (HIPC).
  • METHODS: From 2001 to 2005, 35 consecutive patients with peritoneal metastases enrolled in a prospective trial approved by the University of Minnesota Institutional Review Board.
  • Their primary cancer sites included the appendix (19 patients), colon (7), mesothelioma (3), stomach (2), small bowel (2), gallbladder (1), and unknown (1).
  • We performed CS in an effort to remove all or nearly all peritoneal tumor nodules.
  • Using a closed technique, we administered hyperthermic mitomycin C into the peritoneal cavity for 90 min.
  • Before treatment and then at 4-month postoperative intervals, we used the functional assessment of cancer therapy-colon subscale (FACT-C) instrument to assess the patients' quality of life.
  • CONCLUSIONS: Despite early toxicity, CS plus HIPC may prolong the overall survival rate of patients with peritoneal metastases and improve quality of life measurements.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Hyperthermia, Induced. Mitomycin / therapeutic use. Peritoneal Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Combined Modality Therapy. Female. Hospitalization. Humans. Length of Stay. Male. Middle Aged. Peritoneal Cavity. Prospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013686.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


78. Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH: Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg; 2010;2010:579672
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: From January 1, 2004 to December, 2007 a total of 20 patients with pancreatic malignancies were retrospectively evaluated who underwent pancreatic surgery with synchronous resection of hepatic, adjacent organ, or peritoneal metastases for proven UICC stage IV periampullary cancer of the pancreas.
  • Metastases were located in the liver (n = 14, 70%), peritoneum (n = 5, 25%), and omentum majus (n = 2, 10%).
  • Lymphnode metastases were present in 16 patients (80%).
  • CONCLUSION: Pancreatic resection for M1 periampullary cancer of the pancreas can be performed safely in well-selected patients.
  • [MeSH-major] Carcinoma / secondary. Carcinoma / surgery. Pancreatectomy. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Oncologist. 2008 May;13(5):562-76 [18515741.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):118-27 [17066229.001]
  • [Cites] Br J Surg. 2007 Mar;94(3):265-73 [17318801.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2212-7 [17538165.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):46-51 [17592290.001]
  • [Cites] Z Gastroenterol. 2007 Jun;45(6):487-523 [17607616.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):246-53 [17667503.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S81-6 [17916525.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2484-92 [17941009.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):86-90 [17710505.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):300-9 [18216537.001]
  • [Cites] Surgery. 2002 Dec;132(6):976-82; discussion 982-3 [12490844.001]
  • (PMID = 21197481.001).
  • [ISSN] 1607-8462
  • [Journal-full-title] HPB surgery : a world journal of hepatic, pancreatic and biliary surgery
  • [ISO-abbreviation] HPB Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3010622
  •  go-up   go-down


79. Lai IR, Yeh CC, Yu SC: Laparoscopic liver resection for hepatocellular carcinoma: intermediate follow-up results. Hepatogastroenterology; 2009 Jul-Aug;56(93):1082-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of the recurrences limited in the liver, and one patient had both liver and lung metastasis.
  • No port site or peritoneal metastases were observed.
  • Treatment of recurrence was second resection in one patients and trans-arterial embolization therapy in four other patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760946.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


80. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, Shimada A, Akechi T, Miyashita M, Adachi I, Japan Palliative Oncology Study Group: Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol; 2005 Apr;16(4):640-7
MedlinePlus Health Information. consumer health - Edema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies.
  • BACKGROUND: To explore the association between hydration volume and symptoms during the last 3 weeks of life in terminally ill cancer patients.
  • Subgroup analysis of patients with peritoneal metastases identified statistically significant interaction between hydration group and dehydration/pleural effusion score.

  • MedlinePlus Health Information. consumer health - Dehydration.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684225.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


81. Knigge U, Hansen CP: [Appendiceal carcinoid tumors and goblet cell carcinoids]. Ugeskr Laeger; 2010 May 31;172(22):1678-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases to regional nodes are seen in 10% of CATs larger than two cm.
  • Ovarian or peritoneal metastases are seen in 20% of all GCCATs.
  • Non-resectable GCCATs are treated like colo-rectal cancer.
  • Patients with CAT larger than two cm, involvement of mesoappendix or metastases and all GCCAT should be followed life-long.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20525467.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


82. Misdraji J: Appendiceal mucinous neoplasms: controversial issues. Arch Pathol Lab Med; 2010 Jun;134(6):864-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low grade appendiceal mucinous neoplasms can spread to the peritoneum as pseudomyxoma peritonei even though they are not obviously invasive in the appendix.
  • During the past several decades, several problematic issues surrounding this enigmatic tumor have been debated in the literature, including appropriate nomenclature for the appendiceal tumors and their peritoneal metastases.
  • Next reviewed is the largely resolved controversy about whether ovarian mucinous tumors in this setting are separate primaries or are metastases from the appendiceal tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20524864.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


83. Tsili AC, Tsampoulas C, Charisiadi A, Kalef-Ezra J, Dousias V, Paraskevaidis E, Efremidis SC: Adnexal masses: accuracy of detection and differentiation with multidetector computed tomography. Gynecol Oncol; 2008 Jul;110(1):22-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiplanar reformatted images were evaluated for the presence of an adnexal mass and differentiation between benign and malignant ones, using the surgical and pathologic results as standard of reference.
  • CT findings used to diagnose malignancy were: diameter greater than 4 cm, presence of masses bilaterally, cystic-solid mass, necrosis in a solid lesion, cystic lesion with thick, irregular walls or septa and/or with papillary projections.
  • Presence of ascites, peritoneal metastases and lymphadenopathy was used to confirm malignancy.
  • RESULTS: Histopathologic examination demonstrated 143 adnexal mass lesions, 96 (67%) of which were benign and 47 (33%) malignant.
  • Multidetector CT detected 129 (90%) of the 143 adnexal masses, with an overall accuracy for the diagnosis of malignancy of 89.15%.
  • The MDCT findings that found more predictive of malignancy were the presence of papillary projections in a cystic lesion, necrosis in solid mass and peritoneal metastases.
  • [MeSH-major] Adnexal Diseases / pathology. Adnexal Diseases / radiography. Diagnosis, Differential

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486202.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Karabulut N, Tavasli B, Kiroğlu Y: Intra-abdominal spilled gallstones simulating peritoneal metastasis: CT and MR imaging features (2008: 1b). Eur Radiol; 2008 Apr;18(4):851-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-abdominal spilled gallstones simulating peritoneal metastasis: CT and MR imaging features (2008: 1b).
  • However, the procedure is associated with a number of complications, one of which is the spillage of gallstones into the peritoneal cavity.
  • In the latter case, spilled gallstones in the peritoneal spaces may cause diagnostic difficulty or mimic peritoneal metastasis.
  • We present the computed tomography (CT) and magnetic resonance (MR) imaging features of intra-abdominal gallstone spillage in a case with head and neck neoplasm.
  • Awareness of radiologic features of dropped intraperitoneal gallstones is necessary as they may be mistaken for peritoneal metastases.
  • [MeSH-major] Gallstones / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Cholecystectomy, Laparoscopic / adverse effects. Contrast Media. Diagnosis, Differential. Female. Humans. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351358.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Zhao RW, Yang SH, Cai LQ, Zhang J, Wang J, Wang ZH: [Roles of vascular endothelial growth factor and platelet-derived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]. Zhonghua Fu Chan Ke Za Zhi; 2009 Oct;44(10):760-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) Expression of Prox1, a newly described lymphatic endothelial cell nucleus marker, VEGF-A, VEGF-C, VEGF-D and PDGF-A, PDGF-B, PDGF-C, PDGF-D were detected by RT-PCR in SKOV3 cell line and in 90 ovarian tissue samples, included 15 benign tumors, 10 borderline tumors, 45 malignant tumors and 20 normal ovarian samples. (2) Expression levels of Prox1, VEGF-A, -C, -D and PDGF-A, -B, -C, -D were detected in 90 ovarian tissue sample mentioned above by real-time quantitative PCR (RTQ-PCR). RESULTS:.
  • VEGF-A, -C, -D and PDGF-A, -B, -C, -D were found in SKOV3 cell and various ovarian tissues. (2) Expression levels of Prox1 (2.2 +/- 1.3, P < 0.01), VEGF-A (3.5 +/- 1.5, P < 0.01), VEGF-C (19 +/- 14, P < 0.01), VEGF-D (3.0 +/- 1.8, P < 0.01) and PDGF-A (3.3 +/- 3.3, P < 0.05), PDGF-C (6.9 +/- 4.6, P < 0.01) in malignant group were found to be significantly higher than those in borderline group and benign group. (3) The expression levels of Prox1, VEGF-A and PDGF-A were significantly greater in samples from the patients with lymph node metastasis (Prox1: 3.0 +/- 1.4, VEGF-A: 4.1 +/- 1.7, PDGF-A: 4.9 +/- 4.1), peritoneum metastasis (Prox1: 2.8 +/- 0.9, VEGF-A: 4.0 +/- 1.8, PDGF-A: 4.5 +/- 4.0) and in stage III - IV (Prox1: 2.6 +/- 1.3, VEGF-A: 4.0 +/- 1.4, PDGF-A: 4.1 +/- 3.7) than those without lymph node metastasis, without peritoneum metastasis and in stage I - II.
  • There was a significant increased in the degree of VEGF-C and VEGF-D expression in positive lymph node metastasis group (VEGF-C: 24 +/- 13, VEGF-D: 3.9 +/- 2.0) compared with negative group (P < 0.05). (4) There were significant positive correlations between the expression levels of Prox1 and VEGF-D (r = 0.62, P < 0.01), PDGF-C (r = 0.91, P < 0.01) or PDGF-D (r = 0.61, P < 0.01).
  • CONCLUSIONS: VEGF-A, VEGF-C and PDGF-A may promote lymphatic metastasis in epithelial ovarian carcinoma through else mechanisms other than lymphangiogenesis.
  • VEGF-D may facilitate lymphangiogenesis and lymph node metastasis in epithelial ovarian cancer.
  • There is no significant correlation between the expression of PDGF-B and lymphangiogenesis and lymph node metastasis.
  • PCGF-C and PDGF-D may motivate lymphangiogenesis, but could not participate in lymph node metastasis in ovarian carcinoma.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Vascular Endothelial Growth Factor C. Vascular Endothelial Growth Factor D

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078963.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


86. Hibi T, Ojima H, Sakamoto Y, Kosuge T, Shimada K, Sano T, Sakamoto M, Kitajima M, Yamasaki S: A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential. J Gastroenterol; 2006 Mar;41(3):276-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A solid pseudopapillary tumor arising from the greater omentum followed by multiple metastases with increasing malignant potential.
  • Solid pseudopapillary tumor is a rare, indolent neoplasm almost exclusively seen in the pancreas.
  • We describe an unusual case of solid pseudopapillary tumor arising in the greater omentum of a 45-year-old man with subsequent multiple liver metastases and peritoneal dissemination.
  • We also performed quantitative evaluation of Ki-67 immunoreactivity and mitotic figures, which indicated malignant transformation of this extremely rare tumor.
  • This is the first detailed report of solid pseudopapillary tumor arising outside the pancreas complicated by repetitive liver metastases and peritoneal carcinomatosis, suggesting the existence of a more lethal subgroup of tumors.
  • [MeSH-major] Carcinoma, Papillary / secondary. Omentum / pathology. Pancreatic Neoplasms / secondary. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Fatal Outcome. Humans. Immunohistochemistry. Ki-67 Antigen / blood. Laparotomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Male. Mesentery / pathology. Mesentery / surgery. Middle Aged. alpha 1-Antitrypsin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
  •  go-up   go-down


87. Yoshikawa T, Tsuburaya A, Miyagi Y, Sekiguchi H, Kimura M, Cho H, Kobayashi O: Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res; 2006 Sep-Oct;26(5B):3849-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer.
  • BACKGROUND: Gastric cancer often metastasizes to the peritoneal cavity in which tumor cells are exposed to hypoxia without systemic circulation.
  • Hypoxia-inducible factor-1 (HIF-1) and its target gene, vascular endothelial growth factor (VEGF), may play a role in the development of peritoneal metastases.
  • MATERIALS AND METHODS: The mRNA levels of HIF-1 alpha and VEGF were examined in 21 normal gastric mucosa, 158 primary tumors and 18 peritoneal metastases by quantitative RT-PCR.
  • RESULTS: HIF-1 alpha and VEGF were significantly up-regulated in the peritoneal metastases compared with those of the normal mucosa and the primary tumors.
  • A positive correlation between HIF-1 alpha and VEGF was observed in the peritoneal dissemination.
  • [MeSH-major] Hypoxia-Inducible Factor 1 / genetics. Peritoneal Neoplasms / secondary. RNA, Messenger / genetics. Stomach Neoplasms / pathology. Up-Regulation. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094412.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hypoxia-Inducible Factor 1; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


88. Yamada S, Fujii T, Sugimoto H, Kanazumi N, Kasuya H, Nomoto S, Takeda S, Kodera Y, Nakao A: Pancreatic cancer with distant metastases: a contraindication for radical surgery? Hepatogastroenterology; 2009 May-Jun;56(91-92):881-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer with distant metastases: a contraindication for radical surgery?
  • BACKGROUND/AIMS: The purpose of this study was to analyze cases of resected pancreatic cancer with distant metastasis (M1) and to review the surgical indication for these patients.
  • METHODOLOGY: Between July 1981 and December 2007, 542 patients with pancreatic cancer underwent surgery at the Department of Surgery II, Nagoya University.
  • These patients included 48 cases of paraaortic lymph node metastases, 11 cases of hepatic metastases and 6 cases of peritoneal metastases.
  • As for hepatic metastases and peritoneal metastases, no significant difference in survival was observed between resected and unresected cases.
  • However, survival in cases of paraaortic lymph node metastases was better than that in unresected cases, although this observation was not statistically significant.
  • CONCLUSIONS: Hepatic or peritoneal metastases are contraindications for radical surgery for pancreatic cancer.
  • On the other hand, patients with paraaortic lymph node metastases are relatively promising targets for radical surgery, and radical resection with extended lymphadenectomy remain an option for these patients.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621722.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


89. Sarnaik AA, Sussman JJ, Ahmad SA, McIntyre BC, Lowy AM: Technology for the delivery of hyperthermic intraoperative intraperitoneal chemotherapy: a survey of techniques. Recent Results Cancer Res; 2007;169:75-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal metastases are common sequelae of gastrointestinal malignancy.
  • The treatment of peritoneal metastases through use of aggressive surgical cytoreduction including peritonectomy coupled with HIPEC has now been reported in several large single-institution series.
  • In theory, the coliseum and PCE techniques may have less associated morbidity because of improved heat distribution; however, this remains to be definitively proven in a controlled clinical trial.
  • Such controlled studies are critical to defining the best techniques for HIPEC administration and the appropriate role for this treatment regimen in patients with peritoneal metastases.
  • The development of a program in cytoreductive surgery and HIPEC requires a comprehensive patient care team led by appropriately trained surgeons.
  • Such teams are best suited to provide the highest-quality care to patients with peritoneal surface malignancy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Hyperthermia, Induced. Infusions, Parenteral / methods. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506250.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 18
  •  go-up   go-down


90. Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G, Gruppo Oncologico dell'Italia Meridionale: Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol; 2006 Jun;17 Suppl 7:vii73-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
  • BACKGROUND: The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy.
  • Objective responses were recorded at loco-regional disease, liver and nodal metastases.
  • Lung and peritoneal metastases did not respond.
  • CONCLUSION: The GEM/CDDP regimen is active against advanced and/or metastatic BTC with a favourable toxicity profile.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760299.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Yang ZM, Wu XT, He T, Da MX, Luo T, Qian K: [Study on association between the expression of galectin- 3 and the peritoneal metastasis in gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar;8(2):151-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on association between the expression of galectin- 3 and the peritoneal metastasis in gastric cancer].
  • OBJECTIVE: To investigate the association between the expression of galectin- 3 protein and peritoneal metastasis in gastric cancer.
  • METHOD: The expressions of galectin- 3 was detected in matching- samples including primary gastric cancer lesions,lymph node metastases,peritoneal metastases and paratumor normal tissues by immunohistochemistry.
  • All specimens were gained from 35 patients who had synchronous peritoneal metastasis from gastric cancer.
  • RESULTS: The over- expression of galectin- 3 was observed in 97% (34/35) of the gastric cancer lesions, the peritoneal metastases and the lymph node metastases,whereas in 14% (5/35) of paratumor normal tissues.
  • There were significant differences in the expression of galectin- 3 between paratumor normal tissues and the gastric carcinoma lesions,peritoneal metastases and lymph node metastases (P< 0.05),but there were no significant differences among the gastric cancer lesions,the peritoneal metastases,and the lymph node metastases (P> 0.05).
  • CONCLUSION: The expression of galectin- 3 in gastric cancer lesions can be used as a biological marker of peritoneal metastasis from gastric cancer before operation and as a prognostic factor of gastric cancer.
  • [MeSH-major] Galectin 3 / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Stomach Neoplasms / metabolism
  • [MeSH-minor] Humans. Immunohistochemistry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155829.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


92. Syed R, Nazir SA, Lwin KY, Bose P, Evans P, Choji K: Occurrence of synchronous invasive lobular breast carcinoma and poorly differentiated ovarian carcinoma in a single peritoneal deposit. Oncology; 2007;73(1-2):136-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of synchronous invasive lobular breast carcinoma and poorly differentiated ovarian carcinoma in a single peritoneal deposit.
  • The synchronous occurrence of breast and ovarian cancers within individual omental metastases has not been reported in the available medical literature.
  • We report such a finding in a patient with previously diagnosed invasive lobular carcinoma of the right breast.
  • After 5 years of surveillance and disease-free interval, there was development of ovarian cancer, ascites and peritoneal metastases.
  • Ultrasound-guided biopsy of a peritoneal metastasis confirmed dual histology from breast and ovarian carcinoma.
  • Despite the presence of a prolonged disease-free survival from the primary breast cancer, the subsequent finding of advanced ovarian cancer highlights the potential diagnostic and therapeutic dilemmas which persist in the management of these patients.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / diagnosis. Carcinoma / secondary. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / secondary. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18337627.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


93. Sârbu V, Maciuceanu B, Supeanu I, Dima S, Parvu M, Davidescu C, Plesa D, Iusuf T, Aşchie M, Popescu R, Costea D, Pasăre R, Botea F: [Preliminary results for intraperitoneal chemotherapy in abdominal cancers]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):549-55
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then 20 cases of abdominal cancers with or without peritoneal metastases are presented, in which IPCH was applied using a Romanian apparatus of drainage - lavage with hyperthermic solutions of 5 Fluorouracil, alone or combined with cisplatin, over a 3 years period.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018355.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


94. Kobayashi T, Adachi S, Matsuda Y, Tominaga S: A case of metastatic lobular breast carcinoma with detection of the primary tumor after ten years. Breast Cancer; 2007;14(3):333-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic lobular breast carcinoma with detection of the primary tumor after ten years.
  • Lobular carcinoma of the breast is known to metastasize to unusual sites such as the gastrointestinal tract, peritoneum, and gynecologic organs.
  • We report a patient with intraperitoneal metastases from lobular carcinoma who was originally treated for an unknown primary cancer.
  • Ten years later, a tumor was found in her left breast and the diagnosis was changed to peritoneal metastases from invasive lobular carcinoma.
  • Immunohistochemistry revealed that the metastases were high molecular weight cytokeratin (CK34betaE12) and estrogen receptor-positive, but were E-cadherin-negative.
  • These results assisted in diagnosis.
  • Surgeons should be aware of the characteristics of metastasis lobular carcinoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Lobular / diagnosis. Duodenal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690515.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Odashiro AN, Pereira PR, Odashiro Miiji LN, Nguyen GK: Angiosarcoma of the gallbladder: case report and review of the literature. Can J Gastroenterol; 2005 Apr;19(4):257-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were multiple hepatic, splenic, ovarian and peritoneal metastases and a massive hemoperitoneum consisting of 8 L of blood and blood clots.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Hemangiosarcoma / diagnosis
  • [MeSH-minor] Cholecystectomy. Cholecystitis / diagnosis. Cholelithiasis / diagnosis. Fatal Outcome. Female. Hemoperitoneum / etiology. Humans. Middle Aged. Postoperative Complications

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861270.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 11
  •  go-up   go-down


96. Sugie T, Nagai T, Ohgaki K: [Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery]. Gan To Kagaku Ryoho; 2007 May;34(5):765-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery].
  • Two patients with advanced gastric cancer who underwent gastrectomy and pathological examination were both diagnosed as having Stage IV gastric cancer with distant lymph-node metastases and peritoneal dissemination, respectively.
  • These results suggest that combination therapy with S-1 and low-dose CDDP is effective against advanced gastric cancer.
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Neoplasm Staging. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496454.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


97. Coco C, Rizzo G, Manno A, Mattana C, Verbo A: Surgical treatment of small bowel neoplasms. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):327-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic neoplasms may involve the small intestine via contiguous spread, peritoneal metastases or hematogenous metastases.
  • Because the small intestine is relatively inaccessible to routine endoscopy, diagnosis of small intestinal neoplasms is often delayed for months after onset of symptoms.
  • During last years the increase of small bowel endoscopy and other diagnostic tools allow earlier non-operative diagnosis.
  • Even though radical resection of small bowel cancer plays an important role, the 5 yr overall survival remains low.
  • [MeSH-minor] Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Laparoscopy. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496543.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 51
  •  go-up   go-down


98. Kodera Y, Nakanishi H, Ito S, Misawa K, Ito Y, Nakayama G, Koike M, Fujiwara M, Yamamura Y, Nakao A: Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer. Anticancer Res; 2009 Oct;29(10):4033-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer.
  • BACKGROUND: L1, a 200-220 kDa transmembrane glycoprotein of the immunoglobulin superfamily, has been shown to affect prognosis of various types of cancer and was shown to enhance peritoneal metastasis in ovarian cancer in vivo.
  • PATIENTS AND METHODS: Immunostaining with anti-L1 antibody was performed with 72 surgically resected pT3-stage gastric cancer specimens.
  • RESULTS: L1 was detected in 15 specimens (21%), more often among the intestinal-type cancer.
  • No correlation was observed between L1 expression and presence of free cancer cells in the peritoneal cavity or development of peritoneal carcinomatosis during the follow-up.
  • Nevertheless, prognosis of patients with L1-positive cancer was significantly inferior (p=0.024), particularly among the diffuse-type cancer cases.
  • However, its association with the formation of peritoneal metastases or the presence of free cancer cells in the abdominal cavity was not observed.
  • Further study to identify the role of L1 in gastric cancer progression and metastasis is warranted.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846947.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecule L1
  •  go-up   go-down


99. Antuofermo E, Cocco R, Borzacchiello G, Burrai GP, Meloni F, Bonelli P, Pirino S, Cossu-Rocca P, Bosincu L: Bilateral ovarian malignant mixed Mullerian tumor in a dog. Vet Pathol; 2009 May;46(3):453-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian malignant mixed Mullerian tumor in a dog.
  • Malignant mixed Müllerian tumor (MMMT) is a rare neoplasm of the female genital tract.
  • We report a case of bilateral ovarian MMMT in a 10-year-old female dog.
  • Multiple metastases were observed in the abdominal cavity and pulmonary parenchyma.
  • Metastatic lesions were not mixed.
  • The peritoneal metastases were carcinomatous; pulmonary metastases were sarcomatous.
  • On the basis of similarities to human ovarian MMMT, the diagnosis was heterologous malignant mixed Müllerian tumor of the ovary.
  • [MeSH-minor] Animals. Carcinosarcoma / pathology. Carcinosarcoma / veterinary. Dogs. Female. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176505.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Mutinelli F, Vascellari M, Bozzato E: Unilateral seminoma with multiple visceral metastases in a duck (Anas platyrhynchos). Avian Pathol; 2006 Aug;35(4):327-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral seminoma with multiple visceral metastases in a duck (Anas platyrhynchos).
  • A case of unilateral seminoma with visceral metastases in a Mallard duck (Anas platyrhynchos) is reported.
  • In addition, multiple rough whitish nodules were evident on the pancreas and the visceral peritoneum lining the intestine.
  • Multiple lung metastases were detected on histology.
  • This is the first known report of seminoma with hepatic, pancreatic, pulmonary and peritoneal metastases in a Mallard duck.
  • [MeSH-major] Liver Neoplasms / veterinary. Lung Neoplasms / veterinary. Peritoneal Neoplasms / veterinary. Poultry Diseases / pathology. Seminoma / veterinary. Testicular Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854647.001).
  • [ISSN] 0307-9457
  • [Journal-full-title] Avian pathology : journal of the W.V.P.A
  • [ISO-abbreviation] Avian Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement